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ABSTRACT
T-BET EXPRESSING B CELLS WITH DISTINCT RESIDENCY AND
FUNCTIONAL CHARACTERISTICS GIVE RISE TO PLASMA CELLS
Rebecca L. Rosenthal
Michael P. Cancro
An increasing body of work shows that T-bet+ B cells play important roles
in immune responses to infections a well as in autoimmune diseases. These
studies investigate the kinetics, tissue distribution, and functions of T-bet+ B cells
in a murine influenza infection model. Both T-bet+ and T-bet- HA-specific B cells
emerge early after infection, acquire the memory markers CD73, PD-L2 and
CD80, and persist indefinitely with limited interconversion between T-bet+ and Tbet- B cell pools. Moreover, T-bet+ B cells are required for HA stalk specific
antibodies and sustained protective HAI titers. T-bet+ HA-specific B cells can be
further divided into T-bethigh and T-betlow B cell pools. While T-bethigh, T-betlow, and
T-bet- HA-specific B cells are initially found in the spleen, lungs, and draining
mediastinal lymph nodes; at later timepoints T-bethigh HA-specific memory B cells
are restricted to the spleen, despite the continued presence of T-bet- HA-specific
B cells at other anatomical locations. Parabiotic studies show that HA-specific Tbethigh B cells are splenic residents, whereas T-betlow and T-bet- B cells
recirculate. T-bethigh B cells give rise to T-betlow B cells but T-betlow B cells do not
become T-bethigh. However, T-betlow B cells persist for a minimum of three weeks
in the absence of T-bethigh B cells, indicating that they are likely distinct
populations. CD138 levels increase with decreasing T-bet expression and Tiv

betlow and T-bethigh B cells downregulate T-bet and give rise to plasma cells. Both
B220+ and B220- plasma cells arise from T-bet+ B cells in the spleen and bone
marrow. Together, these data suggest that T-bethigh memory B cells are a unique
splenic resident population with stem cell like properties that sustains plasma cell
numbers and protective antibody titers long term.
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CHAPTER 1: Introduction
1.1 Overview of Innate and Adaptive Immunity
The immune system provides protection from pathogens, but also underlies
diseases such as autoimmunity and allergy. As such, the ability to mount
protective immune responses while preventing the development of autoimmunity
is essential for continued health. Four attributes of the immune response in
vertebrates are key to achieving these goals. These are (1) recognition of an
incipient infection, (2) control/clearance of the infection via immune effector
functions, (3) regulation to prevent/limit immune mediated damage to the host,
and (4) establishment of immunological memory that provides durable protection
from reinfection.
When a pathogen breaches host defenses, including barriers such as the
skin and mucus membranes, innate immune mechanisms provide a rapid firstline of defense. The innate immune system includes myeloid cells such as
granulocytes, dendritic cells, macrophages, and mast cells, that rapidly sense the
pathogen. This is mediated by germ-line encoded pattern recognition receptors
(PRRs) that recognize evolutionarily conserved pathogen associated molecular
patterns (PAMPs) expressed by microbes1, as well as damage associated
molecular patterns (DAMPs) that are released from cells following damage and
death2. Engagement of PRRs by PAMPs and/or DAMPs activates cells of the
innate immune system. Moreover, this activation can result in a spectrum of
1

differentiative programs that in turn will instruct the effector choices undertaken
by the cells participating in the adaptive immune response3.
While the innate immune system generates a rapid response by
recognizing broadly conserved molecular moieties, the adaptive immune system
generates a response that is finely tailored to unique molecular determinants of
the pathogen. Many key aspects of the adaptive response can be explained by
Burnet’s clonal selection paradigm. Fundamental to Burnet’s theory is that each
lymphocyte expresses antigen receptors of a single specificity, and that
occupation of these receptors induces cells to respond and divide, thus
producing daughter cells with the same specificity as the original responding cell.
1.2 B Lymphocyte Development
In adults, B cell development begins in the bone marrow with pluripotent
hematopoietic stem cells that generate multipotent progenitor cells, which have
lost their potential as self-renewing stem cells, but can give rise to both lymphoid
and myeloid cells. These multipotent progenitor cells express the cell surface
receptor tyrosine kinase FLT3, and signaling through this receptor leads to
differentiation into the common lymphoid progenitor (CLP)4, 5, 6, 7. Some CLP
progeny then differentiate into a pro-B cell, which is the first cell type firmly
committed to the B cell lineage. These cells initiate the process of
immunoglobulin (Ig) gene rearrangement, which ultimately leads to expression of
a functional B cell receptor (BCR). The first stage of Ig gene rearrangement
results in rearrangement of the germline heavy chain segment via joining of a
2

diversity (D) gene segment to a joining (JH) gene segment8. In the late pro-B cell,
a variable (VH) gene segment is joined to the previously generated DJH segment.
This can generate a productive VHDJH segment that is expressed as part of the
pre-BCR, together with a surrogate light chain (SLC)9. Proper VHDJH
rearrangement and pairing with the SLC is required for transit to the next stage of
B cell development, and roughly half of pro-B cells fail to successfully complete
this process and are eliminated10. In the next stage of B cell development, the
large pre-B cell undergoes extensive proliferation, expanding 30-60 fold. The
developing B cell then becomes a resting small pre-B cell11, 12, 13. The small pre-B
cell once again expresses RAG and rearranges the germline light chain
sequence to generate a light chain VJ segment14, 15. After a productive light chain
VJ rearrangement, the small pre-B cell becomes an immature B cell and
expresses a full IgM BCR on its surface with both a rearranged heavy and light
chain. The IgM-expressing B cell is subject to positive and negative selection
based on BCR signal strength in order to eliminate autoreactive clones and
identify B cells with signaling-competent receptors. Strikingly, as many as 75% of
immature B cells are initially autoreactive16, 17. Given this stringent selection, only
10% of immature B cells exit the bone marrow into the peripheral lymphoid
organs. Here, they undergo further selection and more than half of the remaining
cells are eliminated prior to entry into the mature B cell pools18, 19, 20, 21, 22.
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1.3 Lymphocyte Effector Subsets
Following antigen encounter and activation, both T and B lymphocytes
undergo further differentiation into distinct effector and memory subsets. For
example, CD4 T cells differentiate into distinct effector lineages characterized by
unique cytokine production profiles and lineage-specific transcription factors that
are required for their differentiation23. These distinct effector lineages have
differing functions, and their proper regulation is key to initiating and maintaining
a protective immune response, as inappropriate effector lineage commitment
leads to failed pathogen clearance and/or autoimmune and inflammatory
pathologies24. The cytokine milieu, as well as T cell receptor (TCR) signaling and
costimulation, determine commitment to a given effector lineage. Similarly, CD8
T cells include distinct effector subsets with specialized functions and distinct
transcription factor profiles. These can differ in terms of tissue residency and
recirculation, which is important for tissue surveillance and protection from
reinfection25. Importantly, resident memory T cells (Trm) fail to recirculate and
remain tissue resident, as demonstrated through parabiosis experiments26, 27, 28.
Most of these Trm are not exposed to circulation as demonstrated by a failure to
label following intravenous fluorescent antibody injection29. These Trm are
important for protective immunity against local reinfection30. For example, in a
local vaccinia virus re-challenge model, mice with skin resident Trm rapidly
cleared reinfection whereas mice lacking Trm failed to control the virus despite
similar levels of central memory T cells26.
4

While the importance of effector T cell subsets with distinct tissue residency
and recirculation properties is appreciated, a similar understanding of the breadth
of memory B cells is ongoing. One way to stratify B cells into various effector
subsets is on the basis of heavy chain isotype. The BCR heavy chain has five
main isotypes; delta, mu, gamma, alpha, and epsilon. These heavy chain
isotypes pair with either a kappa or lambda light chain to form IgD, IgM, IgG, IgA,
or IgE. Furthermore, the IgG isotype can be split into four subtypes; IgG1,
IgG2a/c (with IgG2a present in BALB/c and IgG2c in C57BL/631), IgG2b, and
IgG3 in mice and IgG1, IgG2, IgG3, and IgG4 in humans. Similar to T cell effector
lineages, the cytokine milieu along with receptor signaling are key drivers of class
switch recombination decisions with the various BCR isotypes serving differing
roles in an immune response32, 33. Isotype-specific Fc receptors are expressed on
a range of hematopoietic origin cells. These Fc receptors can be either activating
or inhibitory and as such the Ig isotype has important effects on cell activation
and behavior. These Fc receptor interactions can regulate multiple effector
responses including antibody-dependent cytotoxicity, phagocytosis, and
inflammatory mediator release33.
However, heavy chain isotype is not the only way in which mature B cells can
be divided into distinct subsets. Following antigenic stimulation, B cells can be
recruited into a germinal center (GC) response. These GC B cells can undergo
robust proliferation, with the magnitude of T cell help being an important
determinant of the extent of division. GC B cells acquire point mutations in their
BCR and compete for survival signals, such that higher affinity clones are
5

selected for survival. These high affinity GC B cells go on to become memory B
cells or plasma cells and can even participate in further rounds of GC selection34,
35

. These GC derived memory B cells may be primed for rapid differentiation into

antibody secreting cells upon reexposure36, 37.
Similar to T cells, mature B cells can be divided on the basis of key lineage
commitment transcription factor expression38, 39. The transcription factor T-bet is
characteristic of Age Associated B Cells (ABCs) and will be the focus of the work
discussed here.
1.4 T-bet+ Age Associated B Cells
While previous work demonstrated that T-bet expression in B cells is
important for class switching to the IgG2a/c isotype40, the discovery of a unique B
cell subset characterized by T-bet expression can be credited to the Cancro and
Marrack laboratories41, 42. Despite using different criteria to define this novel B
cell population, both observed an accumulation of these cells in mice with
increasing age and termed them Age Associated B Cells (ABCs). Subsequent
work has demonstrated that they are largely overlapping populations41, 42.
Furthermore, Rubtsov et al. observed that these cells accumulated earlier in
females of various autoimmune prone mouse strains and that a similar cell
population could be found in elderly women with autoimmune conditions42.
ABCs display several unique characteristics. They are refractory to BCR
crosslinking, thus distinguishing them from follicular B cells which robustly
proliferate in response to BCR crosslinking, as well as from marginal zone (MZ)
6

and transitional B cells, which die upon BCR crosslinking41, 43. ABCs proliferate in
response to endosomal Toll Like Receptor (TLR) stimulation. This proliferation
can be enhanced by the addition of BCR stimulation, showing that while ABCs do
not proliferate in response to BCR crosslinking alone, the BCR retains some
signaling capabilities. However, ABCs fail to proliferate in response to TLR4
stimulation as provided by the ligand lipopolysaccharide (LPS), further
distinguishing them from other mature B cell subsets such as MZ B cells which
robustly expand following LPS treatment41, 43.
While ABCs accumulate with age, this does not reflect the emergence of a
distinct precursor population in aged bone marrow. Sublethal irradiation with 500
cGy in aged mice results in the successful ablation of most peripheral B cell
pools including ABCs, follicular B cells, and MZ B cells. Following irradiation, the
ABC pool fails to rapidly autoreconstitute despite the rapid reestablishment of the
follicular and MZ B cell pools. Additionally, adoptive transfer of splenic follicular B
cells gives rise to ABCs within 30 days of transfer and donor or recipient age has
no impact on the formation of these donor derived ABCs. Interestingly, cells with
an ABC phenotype preferentially arise from the fraction of donor cells undergoing
the most robust proliferation following adoptive transfer. While ABCs express the
BAFF/BLyS receptors BAFFr (BR3) and TACI, they do not rely on BAFF
signaling for their survival as ABC numbers are not impacted by treatment with
doses of anti-BAFF antibody sufficient to deplete the follicular and MZ B cell
pools41.
7

A large portion of ABCs express the transcription factor T-bet42. T-bet, or Tbox containing protein expressed in T cells, is a transcription factor encoded by
the Tbx21 gene. It was first described as a master regulator controlling the
commitment of CD4 T cells to a Th1 effector lineage44. Subsequently, it has been
shown to be important for the development, survival, and function of various
innate and adaptive immune cell types45. Its role in B cells has gained increasing
appreciation as T-bet expressing B cells are associated with a range of infections
46, 47, 48, 49, 50, 51, 52, 53, 54, 55

and autoimmune pathologies in both mice and

humans42, 56, 57, 58, 59. T-bet+ B cells likely play an important role in protective
immune responses as mice lacking T-bet expression in B cells show impaired
viral control51, 55.
Requirements for T-bet Expressing B Cell Formation
T-bet expression in B cells was first observed after in vitro treatment of
splenic B cells with CD40, interleukin (IL) 12, and IL-1844. Subsequent work
demonstrated that T-bet promotes B cell isotype switching to IgG2a/c40. T-bet
expression is robustly induced in vitro after treatment of follicular B cells with
either interferon gamma (IFNγ) or IL-21 in the presence of TLR7 or TLR9
agonists60. The addition of IL-4 has differential effects on T-bet induction
depending on whether it is added to IFNγ or IL-21 stimulated B cells: the addition
of IL-4 to IL-21 stimulated follicular B cells blocks T-bet induction whereas
addition of IL-4 to IFNγ stimulated B cells preserves and possibly even enhances
T-bet induction. The IL-4 mediated blockade of IL-21 induced T-bet induction is
8

STAT6 dependent and cell intrinsic. STAT6 knockout follicular B cells co-cultured
with wildtype follicular B cells still upregulate T-bet in response to IL-21 and IL-4
treatment in the presence of a TLR9 agonist. However, cocultured wildtype cells
failed to induce T-bet in response to this combination of stimuli. A large portion of
IL-21 driven T-bet+ B cells express the integrin CD11c whereas IFNγ driven Tbet+ B cells are uniformly CD11c negative60. Together, these results imply that
IFNγ and IL-21 utilize different pathways to drive T-bet induction, and that T-bet
expression alone is insufficient to drive CD11c expression. Thus, T-bet
expression is unlikely to be a simple on/off switch but instead can be driven
through multiple inductive pathways. A similar pattern of T-bet induction can be
observed in vivo, as B6 mice, which show a strong TH1 skewing and resultant
high levels of IFNγ61, have much higher proportions of T-bet expression in GC
and memory B cells than BALB/c mice, which have a TH2 bias and associated
high IL-4 levels61. Infection with the PR8 strain of influenza, which leads to a TH1
skewed response with robust IFNγ, IL-21, and IL-4 production by responding TFH
cells62, results in a strong T-bet+ GC B cell response in wildtype C57BL/6 but not
IFNγ knockout mice, despite a similar magnitude in overall GC B cell response.
The T-bet+ GC B cell response is rescued in IL-4/ IFNγ double knockout mice,
despite an overall decrease in the GC B cell response. Infection of C57BL/6 mice
with the TH2 biased pathogen H. polygyrus, which leads to IL-21 and IL-4
production by TFH cells in the absence of IFNγ63, fails to induce T-bet expression
in the GC B cell response whereas IL-4 knockout mice display robust T-bet and
9

CD11c expression in GC B cells. This is not due to increased IFNγ in IL-4
knockout mice mice, as the T-bet+ CD11c+ GC B cell response is observed in IL4/ IFNγ double knockout mice60.
T-bet Expressing B Cells in Health and Disease
The first demonstration of T-bet+ B cells in pathogen-driven immune
responses was provided by the Winslow lab, who showed that IgM+ CD11c+
splenic plasmablasts64 and memory B cells65 emerge follow Ehrlichia muris
infection in mice. Later work showed that these cells express T-bet66. T-bet+ B
cells emerge following viral infections as first demonstrated by the identification
of T-bet+ CD11c+ B cells following gamma herpes virus 68 infection. These cells
produce virus specific IgG2a and are important for maintaining reduced virus
titers55. Furthermore, T-bet+ B cells are important in controlling lymphocytic
choriomeningitis virus (LCMV) infection, as T-bet+ B cells are required for LCMV
specific IgG2a production. While not required for control of acute LCMV infection,
T-bet+ B cells are required for viral control during chronic infection. Serum
transfer of LCMV specific IgG2a into infected mice with B cells lacking T-bet was
unable to control chronic LCMV viral loads, indicating that T-bet+ B cells have
important roles in viral control beyond IgG2a production51.
These results indicate that T-bet+ B cells are likely a memory B cell
population. They persist long term following viral infection and clearance, as
evidenced by the sustained presence of antigen specific T-bet+ B cells in mice
following clearance of influenza infection47. Studies in humans have
10

demonstrated the persistence of T-bet+ B cells in aviremic HIV patients after
years of successful antiretroviral therapy52.
T-bet+ B cells are also important in autoimmunity. T-bet+ B cells or B cells with
T-bet associated phenotypes can be observed at increased frequencies in
patients with a wide range of autoimmune pathologies, such as lupus, multiple
sclerosis, rheumatoid arthritis, Crohn’s disease, celiac disease, common variable
immune deficiency, Sjogren’s syndrome, and hepatitis associated mixed
cryoglobulinemia56, 59, 67, 68, 69, 70, 71, 72, 73, 74, 75.
1.5 Scope
T-bet+ B cells are induced and persist in response to pathogen challenge, but
outstanding questions regarding their kinetics, residency and function remain. In
chapter 2, we examined the emergence and persistence of T-bet+ B cells
following influenza infection and tested their contribution to the humoral
response. As T-bethigh B cells display progressive splenic restriction, we tested
their residency using parabiosis. In chapter 3, we further investigated the fate of
T-bet+ B cells by examining their ability to differentiate into other cell types,
including plasma cells. We found that spleen resident T-bethigh memory B cells
likely differentiate into a circulating population that eventually gives rise to plasma
cells in the spleen and bone marrow.
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CHAPTER 2: The Emergence, Maintenance, and Residency of T-bet+ B Cells
in an Influenza Response
2.1 Summary
In this section, we track the emergence and maintenance of influenza
hemagglutinin (HA) specific B cells following influenza infection in mice. Using a
T-bet ZsGreen reporter mouse strain, we show that a portion of HA-specific B
cells express the transcription factor T-bet. While T-bet- HA-specific B cells can
be found in both the spleen and draining mediastinal lymph nodes (LNs) long
term following infection, T-bet+ memory B cells are largely restricted to the spleen
at memory time points and are absent from the lymphatics. Using parabiosis, we
demonstrate that while T-bet- and T-betlow HA-specific B cells traffic and are
found in the spleens of both partner mice, T-bethigh HA-specific B cells are
restricted to the spleen of the previously infected partner, indicating that they are
sessile splenic residents. T-bet+ B cells are important in generating influenza
specific IgG2a/c titers as these are greatly reduced in mice lacking T-bet
expressing B cells. Furthermore, HA stalk titers are nearly absent in mice without
T-bet+ B cells. While HAI titers are similar between all genotypes at day 15 post
infection, they are significantly reduced by day 40 in mice lacking T-bet
expression in B cells, indicating that T-bet is likely required for sustained
protective immune titers.
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2.2 Introduction
The importance of T-bet in immune responses was first recognized in
studies from the Glimcher lab, that showed T-bet is a key transcription factor in
driving CD4 T cell commitment to a T helper 1 (Th1) cell fate44. Later work
showed that T-bet is involved in the development and effector functions of
various innate and adaptive immune cell types45. As such, there is an increasing
appreciation of T-bet as a key feature of immune cells in type 1 immune
responses.
T-bet plays an important role in protection, recovery, and/or pathogen
burden in a range of infections. T-bet deficient mice show an increased incidence
and severity of septic arthritis and increased renal bacterial counts following
Staphylococcus aureus infection76. Mice lacking T-bet are more susceptible to
aerosol or IV Mycobacterium tuberculosis infection as demonstrated by
decreased survival and increased bacterial burdens in the lungs, liver, and
spleen77. Furthermore, T-bet knockout mice have decreased survival and
increased splenic bacterial counts after Salmonella typhimurium infection78. In
terms of Francisella tularensis infection, T-bet knockout mice were more
susceptible to death, even at lower doses than wildtype mice, and showed
increased bacterial burdens in the spleen, liver, and lungs regardless of route of
infection. They also displayed an increased susceptibility to re-challenge, as
evidenced by increased death following high dose intra-nasal secondary infection
following intra-dermal or intra-nasal vaccination79. This is further supported by
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studies demonstrating a link between strength of Francisella vaccine engendered
protection and magnitude of upregulation of T-bet expression80. However, not all
immune protection following bacterial infection relies on T-bet. T-bet deficient
mice do not show impaired Listeria monocytogenes bacterial control and
clearance during the innate or adaptive phases of the response81. In terms of the
intracellular protozoan Leishmania major, T-bet-/- C57/BL6 mice were more
susceptible than their wildtype littermate controls and showed a similar failure to
resolve lesions and control pathogen burden as the susceptible Th2 biased
BALB/c mouse strain82.
Furthermore, T-bet is important in controlling certain viral infections. Mice
lacking T-bet had increased viral titers, accelerated disease onset, and impaired
survival following genital Herpes Simplex Virus Type 2 infection. This impaired
protection extended to secondary responses as T-bet-/- mice receiving an
attenuated virus vaccine had impaired control of viral replication and increased
disease severity, viral titers, and death after secondary infection83. Mice lacking
T-bet were more susceptible to Vaccinia virus infection as evidenced by
decreased survival, increased weight loss, and greater persistence of viral
titers84. While T-bet deficient mice did not display impaired viral clearance
following rhinovirus infection, they failed to generate robust antiviral IgG2c titers
and displayed exacerbated viral mediated airway inflammation as evidenced by
increased airway eosinophilia and mucus hypersecretion85.
While T-bet is clearly a key mediator in the response to a variety of
pathogens, the majority of studies have relied on global T-bet knockout mice. As
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such, the observed effects may be related to a failure to generate Th1 polarized
CD4 T cells and therefore decreased IFNγ production. The specific role of T-bet
expressing B cells in immune protection remains less clear and may be
complicated by B cell/T cell interactions such that T-bet deficiency in either T
cells or B cells may have effects on other cell types. Research from the Wherry
lab suggests that T-bet expressing B cells may be important in the control of
chronic viral infections, as mice lacking T-bet in B cells are unable to control
chronic LCMV infection51. It remains unknown whether T-bet expression can be
used to stratify memory B cells into subsets with distinct characteristics and
functions.
In this chapter, we investigate the kinetics, anatomic residency, trafficking,
and function of T-bet+ B cells in mice following influenza infection. We show that
HA-specific B cells can be divided into T-bet-, T-betlow, and T-bethigh populations.
Whereas all three populations are initially observed in the spleen, lungs, and
draining LNs, the T-bethigh population is restricted to the spleen at memory
timepoints and remains resident following parabiosis whereas the T-bet- and Tbetlow populations recirculate and can be found in the spleen of the partner
mouse. We demonstrate that B cell specific T-bet expression is required for the
development of HA-specific IgG2c titers and stalk specific antibody and durable
neutralizing antibody titers. Together, these findings show that T-bet expression
is an important attribute of the B cell response to influenza infection and can be
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used to delineate memory B cell populations that differ in terms of residency,
recirculation, and functional properties.
2.3 Results
2.3.1 Emergence and Maintenance of HA-Specific T-bet+ B Cells in the Spleen
While previous studies established the presence of T-bet+ HA-specific B
cells in the spleen 100 days post PR8 influenza infection47, we wanted to
undertake a detailed study of the kinetics of the emergence and maintenance of
these cells. We utilized Tg(Tbx21-ZsGreen)E3ZJfz mice (hereafter referred to as
T-bet ZsGreen) that are transgenic for a bacterial artificial chromosome (BAC)
that reports T-bet expression using the fluorescent protein ZsGreen86. We
infected T-bet ZsGreen reporter mice with the 30 TCID50 of influenza A/Puerto
Rico/8/1934 (PR8) and verified successful infection via weight loss. As expected,
mice initially lost weight following infection reaching the nadir at day 9 and then
recovered over the following weeks (Figure 1A). We first wanted to determine the
number and T-bet expression status of HA-specific B cells at various timepoints
following infection. We used a double labelling technique in which biotinylated
PR8 hemagglutinin was coupled to either Brilliant Violet 421 (BV421) or Alexa
Flour 647 (AF647) fluorescently labelled streptavidin molecules in order to create
a HA-biotin streptavidin “tetramer”. HA-specific B cells were identified as a
double positive population binding to both of the HA-biotin streptavidin
“tetramers”. This double labelling strategy greatly improved the specificity of
detection for HA-specific B cells.
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As expected, prior to infection HA-specific B cells are present at very low
precursor frequencies. This is in line with prior estimates of ∼1/50,000 splenic B
cells (Figure 1B)87. For future analysis, we excluded this naïve primary B cell pool
by focusing on IgD- B cells (Figure 1C). Following infection, the HA-specific B cell
population undergoes rapid expansion, reaching peak numbers at 15 days post
infection. The HA-specific splenic B cell numbers then contract, but remain
present at higher frequencies than observed prior to infection for at least 100
days (Figure 1E).
We next assessed the T-bet expression status of these HA-specific B
cells. Prior to infection, HA-specific B cells were uniformly negative for the
transcription factor T-bet (Figure 1B). By day 7 post-infection, about 20% of HAspecific B cells are positive for T-bet, and a portion of the highest T-bet
expressing cells express the integrin CD11c. We stratified these T-bet+ B cells
into T-bethigh and T-betlow populations. Using qPCR for Tbx21 expression, we
showed that both T-bethigh and T-betlow populations express increased T-bet
levels as compared to T-bet- or CD19Cre/WT T-betfl/fl B cells (Figure 1D). This
indicates that both T-bethigh and T-betlow B cells represent bona fide T-bet
expressing B cell populations. Furthermore, we compared the T-bet ZsGreen
expression levels observed in these populations to that seen in canonical T-bet+
CD21- CD23- ABCs (Figure 1C). At all timepoints analyzed following PR8
influenza infection, a similar fraction of HA-specific B cells were in the T-bethigh,
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T-betlow, and T-bet- populations, indicating that antigen specific T-bet+ B cells
persist in the spleen following PR8 influenza infection (Figure 1E).
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Figure 1: Emergence and Maintenance of HA-Specific T-bet+ B Cells in the
Spleen
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T-bet-ZsGreen reporters were intranasally infected with 30 TCID50 influenza
A/Puerto Rico/8/1934 (PR8) (A) Weight loss and recovery from PR8 influenza
infection in T-bet-ZsGreen mice compared to PBS-treated controls. (B)
Fluorescently-conjugated PR8 hemagglutinin (HA) detects the precursor
frequency of HA-specific (HA+) B cells in naïve T-bet-ZsGreen mice, which are
uniformly T-bet-. The naïve precursor frequency per 100,000 B cells is plotted.
(C) Gating scheme for the identification of HA-specific B cells in T-bet-ZsGreen
mice and subsetting into T-bet-, T-betlow, and T-bethigh populations via flow
cytometry. C57Bl/6 mice are included in the T-bet-ZsGreen expression plot as a
control. (D) Tbx21 expression in sorted T-bet-, T-betlow, and T-bethigh B cell
subsets via qPCR. CD19+ B cells were sorted into the corresponding subsets
according to ZsGreen expression (C), and RNA was isolated and cDNA prepared
for qRT-PCR analysis. (E) Fluorescently-conjugated PR8 hemagglutinin (HA)
detects HA-specific B cells, and T-bet-ZsGreen expression in HA-specific B cells
resolves T-bet-, T-betlow, and T-bethigh subsets in the spleen at acute (day 15) and
memory (day 100) timepoints. Number of HA-specific B cells in the spleen at
various time points after infection (top), and proportions of HA-specific B cells
that are T-bet-, T-betlow, and T-bethigh (bottom). Data in (B), (D), and (E) are
plotted as mean ± SEM. **p<0.01 Data in (E) are representative of or compiled
from 2 independent experiments with at least 3 mice per experiment. HA-specific
B cells were identified as live, singlet, DUMP-, B220+, CD19+, IgD- cells, HABV421+, HA-AF647+ cells. DUMP gate includes CD4, CD8, Gr-1, and F4/80.
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2.3.2 Germinal Center and Memory Marker Expression in Splenic HA-Specific B
Cells
We wanted to further define HA-specific T-bet+ B cells to determine if they
differed from T-bet- HA-specific B cells in terms of GC or memory marker
expression. We performed surface staining for GL7, CD95 (FAS), CD38, CD80,
PD-L2, and CD73 at various timepoints following infection. GC B cells are
positive for peanut agglutinin (PNA) binding and typically express increased
levels of GL7 and CD95, and decreased levels of CD38 when compared to naïve
follicular B cells88, 89, 90. For our analyses, we classified GL7+ CD38- B cells as
GC B cells and GL7- CD38+ B cells as memory B cells and analyzed both the
absolute numbers and relative frequencies of these populations within HAspecific B cells (Figure 2A). To further demonstrate the validity of this gating
strategy, we demonstrated that there was good correspondence between GL7
and other GC markers such as CD95 at all measured timepoints (Figure 2B). By
day 7 post PR8 infection, a fraction of HA-specific B cells are beginning to
express a GC phenotype as evidenced by increased GL7 expression; however a
large portion of HA-specific B cells have not yet assumed this phenotype (Figure
2A). The T-bet+ HA-specific B cell fraction likely enters the GC response earlier
than the T-bet- subset, as a higher portion of T-bet+ B cells have upregulated
GL7 by day 7 post infection (Figure 2A). Regardless, a large fraction of these
cells have not yet downregulated CD38, consistent with a pre-GC phenotype89, 91
(Figure 2A). By day 15, the vast majority of T-bet+ and T-bet- B cells have
assumed a GC phenotype, as evidenced by increased GL7 decreased CD38
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levels (Figure 2A). This same phenotype is observed at day 22, but by day 40 a
large portion of HA-specific B cells are exiting the GC as they have begun
downregulating GL7 while CD38 is beginning to increase (Figure 2A). The T-bet+
HA-specific B cells likely exit the GC earlier than the T-bet- B cells as a higher
portion of the T-bet+ B cells no longer express the GC phenotype at day 40
(Figure 2A). By day 100, virtually all T-bet+ and T-bet- HA-specific B cells fail to
express increased levels of GL7, indicating that the GC response has subsided
(Figure 2A). At later timepoints, a large portion of T-bet+ and T-bet- HA-specific B
cells have upregulated CD73, and this is most pronounced at day 100 (Figure
2C). Increased CD73 expression is consistent with a GC origin for most T-bet+
and T-bet- HA-specific memory B cells91, 92.
In a broad sense, memory B cells can be defined as B cells that have
responded to antigen, returned to a resting state, and remain present in
expanded numbers indefinitely post exposure. These cells should be able to
participate in the context of a re-challenge; contributing to a rapid memory
response93, 94. Beyond this, memory B cells express a defined pattern of surface
markers as described by Shlomchick and others36. By day 40, most T-bet+ B cells
are post GC and express memory markers whereas a large portion of T-bet- B
cells still show a GC phenotype and have not yet upregulated memory markers.
The memory marker CD80 first rises during acute infection and undergoes a
further increase starting at day 40 post infection (Figure 2C). CD73 and PD-L2
stay at low levels on HA-specific B cells until days 15-22 when they start to
increase concomitant with commitment to a memory B cell fate (Figure 2C).
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CD80, CD73, and PD-L2 can be seen at their highest levels in both T-bet+ and Tbet- HA-specific B cells at day 100 post infection, consistent with establishment of
a stable memory B cell pool (Figure 2C). Overall, T-bet+ and T-bet- HA-specific B
cells have a shared GC and memory marker expression pattern, although T-bet+
B cells may have somewhat accelerated kinetics.
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Figure 2: Germinal Center and Memory Marker Expression of Splenic HASpecific B Cells
T-bet-ZsGreen reporters were intranasally infected with 30 TCID50 influenza
A/Puerto Rico/8/1934 (PR8) (A) Gating scheme identifies splenic HA-specific
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(HA+) germinal center (GC) B cell (GL7+CD38-), memory B cell (MBC) (GL7CD38+), and pre-GC B cell (CD38+GL7+) subsets; concatenated flow plots
(bottom) depict CD38 and GL7 expression of T-bet+ (pooled T-betlow and Tbethigh; green) and T-bet- (purple) HA-specific B cells at each time point (bottom).
Line plots (top) depict number of HA-specific GC B cells and MBCs separated by
T-bet expression phenotype over time (B) Expression of GL7 and CD95 on T-betand T-bet+ splenic HA-specific B cells at the indicated time points post PR8
infection. (C) Expression of memory markers (CD80, PD-L2, CD73) in T-bet+
(green) and T-bet- (purple) splenic HA-specific MBCs (GL7-CD38+) and naive
follicular B cells (IgD+; grey). Data in (A), (B), and (C) are representative of 2
independent experiments with at least 3 mice per experiment. Data in (A) are
plotted as mean ± SEM. HA-specific B cells were identified as live, singlet,
DUMP-, B220+, CD19+, IgD- cells, HA-BV421+, HA-AF647+ cells. DUMP gate
includes CD4, CD8, Gr-1, and F4/80.
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2.3.3 Tissue Localization of HA-Specific B Cells
In addition to investigating the dynamics of splenic T-bet+ and T-bet- HAspecific B cells following influenza infection, we wanted to track the appearance
of these cells in other tissues. As expected, following influenza infection we
observed a rapid expansion of HA-specific B cells in the mediastinal LNs, lungs,
and blood (Figure 3A). HA-specific B cells were especially prevalent in the
mediastinal LNs, often reaching frequencies as high as 5% of total IgD- B cells
(Figure 3A). As seen in the spleen (Figure 1D), after resolution of influenza
infection, these HA-specific B cells underwent contraction, but remained present
long term at numbers and frequencies higher than those seen prior to infection
(Figure 3A). The kinetics showed some variance among tissues, with HA-specific
B cell numbers in the mediastinal LNs and blood peaking at day 22, whereas in
the spleen and lungs these numbers reached their highest point at day 15 post
infection (Figures 1D; 3A). Strikingly, while T-bet- and T-bet+ B cells remained
relatively constant in their proportions throughout the immune response in the
spleen, comprising about a quarter of HA-specific B cells (Figure 1D), a different
pattern was observed in the mediastinal LNs and lungs. While early on in the
response T-bet+ B cells were evident, their contribution waned with time, a trend
particularly obvious with the T-bethigh HA-specific B cells (Figure 3A). Despite
very low HA-specific B cell numbers in the lungs at day 7 post infection, nearly all
these cells expressed high levels of T-bet (Figure 3A). By day 15, the number of
HA-specific B cells in the lungs had greatly increased and roughly half of these
cells were T-bethigh. By day 40 post infection, HA-specific B cells in the lungs had
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undergone extensive contraction and very few of these cells expressed high
levels of T-bet (Figure 3A). In the mediastinal LNs, at day 7 post infection roughly
75% of HA-specific B cells expressed T-bet and slightly more than a third of
these could be classed as T-bethigh (Figure 3A). By day 15, none of the HAspecific B cells were T-bethigh and the T-betlow population had also significantly
waned (Figure 3A). A similar pattern was observed in the blood, albeit with
somewhat delayed kinetics (Figure 3A). While HA-specific B cells are observed
long term at increased frequencies in the spleens, mediastinal LNs, lungs, and
blood of infected mice, the T-bethigh population persists long term in the spleen
and not in other tissues. Low numbers of HA-specific B cells were observed in
pooled peripheral (superficial cervical, axillary, brachial, and inguinal) and
mesenteric LNs, but this contribution to the response was much smaller than that
observed in the spleen and mediastinal LNs with the T-bethigh fraction nearly
absent by day 100 (Figure 3B).

27

Figure 3: Tissue Restriction of T-bet+ HA-Specific B Cells
T-bet-ZsGreen reporters were intranasally infected with 30 TCID50 influenza
A/Puerto Rico/8/1934 (PR8) (A) Fluorescently-conjugated PR8 hemagglutinin
(HA) detects HA-specific (HA+) B cells, and T-bet-ZsGreen expression in HAspecific B cells resolves T-bet-, T-betlow, and T-bethigh subsets in the mediastinal
lymph nodes (medLN) and lungs at acute (day 15) and memory (day 100)
timepoints. Number of HA-specific B cells in the mediastinal lymph nodes, lungs,
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and blood at different time points after infection (left), and proportions of HAspecific B cells that are T-bet-, T-betlow, and T-bethigh in each tissue (right). The
number of HA-specific B cells in blood was estimated by calculating their
frequency per 100,000 B cells, and proportions of T-bet-defined subsets in blood
were calculated after concatenation due to low cell number. (B) Number of HAspecific B cells in peripheral and mesenteric lymph nodes (LN) by T-bet
expression phenotype at different time points after infection. Data in (A) and (B)
are representative of or compiled from 2 independent experiments with at least 3
mice per experiment and are plotted as mean ± SEM. HA-specific B cells were
identified as live, singlet, DUMP-, B220+, CD19+, IgD- cells, HA-BV421+, HAAF647+ cells. DUMP gate includes CD4, CD8, Gr-1, and F4/80.
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2.3.4 Tissue Residence of HA-Specific B Cells is Stratified by T-bet Expression
The splenic restriction of T-bet+ HA-specific B cells at memory timepoints
raised the question of whether this population might be splenic resident. In order
to investigate this question, we undertook a parabiosis based approach. A T-bet
ZsGreen reporter mouse infected 40+ days prior with PR8 influenza was
surgically joined to an uninfected congenic partner. These mice established a
shared circulatory system after which they were euthanized and the presence of
T-bet+ and T-bet- HA-specific B cells was analyzed in each partner. As virtually
all HA-specific memory B cells arise in previously infected T-bet ZsGreen
partner, we reasoned that the presence of these cells in the B6.SJL partner
suggests that they are a recirculating population. As a confirmation of successful
anastomosis and establishment of a shared circulatory system, sequential tail
bleeds were performed on both partner mice. By day 7 post-surgery, we
observed mixing of CD45.1 and CD45.2 B cells in the blood of both partner mice,
with these populations achieving stable proportions between partners by day 14
(Figure 4A). This is in accordance with previous studies calculating complete
blood exchange occurring between parabiotic partners within 12 days of
surgery95. As such, parabiosed pairs were euthanized at ≥ 17 days post-surgery.
Similar frequencies of CD45.2+ IgD+ B cells, which we expect to recirculate freely
between partners, were observed in the spleen, lungs, and mediastinal LNs of
each partner, suggesting equilibration of recirculating B cells within 17 days of
surgery (Figure 4B).
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HA-specific IgD- memory B cells were identified in the spleen of both
partners, and nearly all of these cells were CD45.2+, consistent with their origin in
the previously infected T-bet ZsGreen partner (Figure 4C). Within the HA-specific
IgD- memory B cell population, T-bet- and T-betlow B cells were identified in the
spleens of both partners. While the number of cells in both of these populations
was significantly lower in the uninfected B6.SJL partner (Figure 4D), this
difference was no longer apparent after normalizing for differing numbers of
CD45.2+ B cells in the spleens of the two partner mice (Figure 4E). This indicates
that T-bet- and T-betlow HA-specific B cells are likely a freely recirculating
population. Importantly, T-bethigh HA-specific B cells were virtually absent from
the spleen of the uninfected B6.SJL partner, despite being present in the spleen
of the previously infected T-bet ZsGreen partner (Figure 4D; 4E). A similar trend
showing a selective failure of HA-specific T-bethigh B cells to recirculate to the
partner spleen can be appreciated when looking at the portion of HA-specific B
cells that belong to the T-bethigh, T-bet-, or T-betlow population (Figure 4F). This
near absence of T-bethigh HA-specific B cells in the B6. SJL partner spleen was
apparent even when data was concatenated from 7 parabiotic pairs (Figure 4G).
To confirm that ZsGreen-expressing cells were not being rejected in the
B6.SJL mice, we measured frequencies of CXCR3+CD8+ lymphocytes, which
highly express T-bet-ZsGreen, and found similar frequencies of these cells in
both partners (Figure 4H). T-betlow HA-specific B cells were present in the
spleens of both mice (Figure 4D; 4E; 4F), together suggesting that broad
rejection of ZsGreen+ cells is not occurring. These observations confirm previous
31

studies that failed to detect an immunogenic response to ZsGreen protein in
C57Bl/6 mice96. Taken together, these findings identify splenic T-bethigh HAspecific B cells as a tissue-resident memory pool.
We next investigated whether HA-specific memory B cells show evidence
of residency in the mediastinal LNs and lungs, the other primary locations of
influenza memory B cells, as others recently demonstrated97. We identified
significant IgD- HA-specific memory B cell populations in the mediastinal LNs and
lungs of the previously infected partner, but these cells were absent in the
uninfected partner, suggesting they are tissue resident populations (Figure 4I;
4J). Interestingly, nearly all mediastinal LN and lung-localized HA-specific B cells
were negative for T-bet (Figure 4K; 4L). However, this residency phenotype may
reflect persistent GCs as GL7+ CD38- HA-specific B cells are observed in the
mediastinal LNs as much as 100 days post infection (Figure 4M). Together,
these results demonstrate that tissue-resident HA-specific B cell memory is
anatomically compartmentalized, comprised of T-bethigh B cells in the spleen and
T-bet- B cell populations in mediastinal LNs and lungs.
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Figure 4: T-bet expression resolves spleen resident versus recirculating
memory B cell pools
(A) T-bet-ZsGreen reporters (CD45.2+; ≥ 40 days post infection) and uninfected
B6.SJL (CD45.1+) were surgically conjoined and showed evidence of blood
sharing by day 7, with equilibrium reached by day 14. Parabionts were
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euthanized at ≥ 17 days post-surgery for analysis. (B) Frequencies of naïve
follicular (IgD+) B cells expressing CD45.2 in lymphoid and non-lymphoid tissues
from each parabiosis pair. (C) Identification of HA-specific IgD- B cells expressing
either CD45.1 or CD45.2 in parabiosis partners. (D) Numbers of T-bet-, T-betlow,
and T-bethigh HA-specific (HA+) splenic memory B cells (MBCs) in T-bet-ZsGreen
(red) and B6.SJL (black) partners. (E) Numbers of T-bet-, T-betlow, and T-bethigh
HA-specific splenic memory B cells per 106 CD45.2+ B cells in T-bet-ZsGreen
(red) and B6.SJL (black) partners. (F) Percentage of splenic HA-specific memory
B cells that are T-bet-, T-betlow, or T-bethigh in parabiosis partners. (G)
Identification of T-bet-ZsGreen reporter-derived (CD45.2+) T-bet-, T-betlow, and Tbethigh HA-specific memory B cells in spleens of T-bet-ZsGreen and B6.SJL
partners; data concatenated from 7 pairs. (H) The percent of splenic CD45.2+
CD8+ T cells that are T-bet-ZsGreen+ CXCR3+ in each partner after ≥17 days of
parabiosis from 7 parabiotic pairs. (I and J) Number of HA-specific memory B
cells in mediastinal lymph nodes (medLN) (I) and lungs (J) of parabiosis
partners. (K and L) T-bet-ZsGreen expression in HA-specific memory B cells
from mediastinal lymph nodes (K) and lungs (L) of T-bet-ZsGreen partner. HAspecific memory B cells were not detected in the mediastinal lymph nodes or
lung of the B6.SJL partner. Data displayed are from 8 pairs across three
independent experiments for spleen and 4 pairs across two-independent
experiments for mediastinal lymph nodes and lungs. HA-specific memory B cells
were identified as live, singlet, DUMP-, B220+, CD19+, CD45.2+, IgD-, HABV421+, HA-AF647+ cells. (M) The percentage of HA-specific memory B cells
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that are GL7+CD38- in the mediastinal lymph nodes and lungs of T-bet-ZsGreen
mice 100 days post PR8 infection, and the percentage that are T-bet+ in each
tissue (top). HA-specific memory B cells cells were identified as live, singlet,
DUMP-, B220+, CD19+, IgD-, HA-AF647+, HA-BV421+ cells. DUMP gate includes
CD4, CD8, Gr-1, and F4/80. Data in (D), (E), (F), (I), (J), and (M) show individual
points with the mean ± SEM indicated. Statistical comparisons performed using
paired two-tailed t-test. ns = not significant, *p<0.05, **p<0.01, ***p<0.001,
****p<0.001
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2.3.5 Influence of B Cell Specific T-bet Expression on Antibody Isotype, Titers,
and Specificity Following Influenza Infection
T-bet promotes class switching to the IgG2a/c isotype in mice and this
isotype is important for multiple anti-viral and anti-bacterial responses, including
influenza40, 55, 98, 99, 100, 101, 102, 103. As such, we compared the betapropiolactone
(BPL) inactivated PR8 (PR8) and PR8 hemagglutinin (HA) specific IgG2c and
IgG1 titers at various timepoints post PR8 influenza infection. We observed that
titers peaked around day 21 and PR8-specific IgG2c and HA-specific IgG2c titers
showed a greater increase than IgG1, evident by days 12 and 15 post infection,
respectively (Figure 5A; 5B). This is consistent with prior studies104 and implies
that T-bet likely plays a key role in antibody production following influenza
infection.
We wanted to explore the role of B cell specific T-bet expression on the
PR8 influenza response. In order to investigate this, we infected B cell-specific Tbet conditional knockout mice obtained by crossing Cd19tm1(cre)Cgn mice with
Tbx21Flox/Flox mice (referred to as cKOs), heterozygous Cd19tm1(cre)Cgn cre controls
(CD19 Cre), and wild type C57Bl/6 mice with PR8 influenza and interrogated the
response in the three groups. All three groups showed similar weight loss
kinetics, although the CD19 Cre controls had less overall weight loss and
recovered lost weight faster (Figure 5C). The three groups had similar numbers
of total HA-specific B cells at both day 15 and day 40 post infection (Figure 5D)
along with an intact HA-specific GC response at day 15 (Figure 5E). As such,
CD19 heterozygosity does not significantly impair the response to influenza
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infection. Furthermore, an HA-specific B cell response can be initiated and
maintained in the absence of T-bet expression in B cells.
We next explored the effect of B lineage T-bet deletion on antibody
functionality as measured by hemagglutination inhibition (HAI) assay. At day 15
post infection, the majority of mice in all three groups had HAI titers of at least 40,
a level associated with protection in human studies105, 106 although a subset of
cKO and wildtype mice had titers of 20 and below (Figure 5F). By day 40 post
infection, HAI titers had decreased in all three groups, likely reflecting a decline in
acute infection related IgM titers107 (Figure 5F). This decrease in titers was
particularly notable in the cKO group, as by day 40 these mice had significantly
lower HAI titers as compared to the wildtype or CD19-Cre controls and the
majority of cKOs at day 40 had sub-protective levels of titers (Figure 5F). This
implies that B cell specific T-bet expression may be required for sustained
protective titers following influenza infection.
We proceeded to determine if the lower HAI titers in cKOs may be related
to loss of a specific component of the antibody response. As expected, cKOs had
significantly lower total BPL-inactivated PR8 IgG2c titers at both day 15 and 40
post infection (Figure 5G). At day 15, cKOs had low IgG2c titers but these were
nearly absent by day 40 post infection (Figure 5G), implying that T-betindependent mechanisms may initiate limited IgG2c switching during acute
infection but B cell specific expression of T-bet is required for sustained IgG2c
PR8-specific titers. We measured PR8 HA-specific titers as HA is a key antigenic
target for protective humoral immunity to influenza. At both day 15 and 40 post
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infection, wildtype and CD19-Cre control mice had robust anti-PR8-HA IgG2c
titers while these were largely absent in the cKO mice (Figure 5H), implying that
B cell intrinsic T-bet is important for both an acute and sustained IgG2c response
to PR8 HA. Furthermore, we measured IgG1 titers to both BPL-inactivated PR8
and PR8 HA as this is a T-bet independent isotype. These titers were similar in
all three groups at both days 15 and 40 post infection (Figure 5G; 5H) and did not
undergo a compensatory increase in response to the lower IgG2c titers in cKO
mice. While the majority of the influenza specific IgG2c response requires B cell
specific T-bet expression; the IgG2c independent components of this response
are preserved in the absence of T-bet expression in B cells.
Finally, we explored whether B cell specific T-bet expression is required
for the influenza antibody response to defined specificities. Specifically, we
explored the HA stalk specific antibody response as recent studies have shown a
key role of HA-specific IgG2a/c antibodies for in vivo influenza protection, which
are largely skewed toward stalk recognition108, 109. We measured IgG2c and IgG1
titers to a chimeric construct comprised of the PR8-related H1 stalk and an
unrelated H6 head110, 111. This allows us to selectively identify stalk specific
antibodies as most PR8-generated HA head-binding antibodies are strainspecific and do not recognize the unrelated H6 head. In wildtype mice, this stalk
specific antibody response is dominated by IgG2c at both early and late
timepoints and IgG1 stalk titers are negligible at both timepoints (Figure 5I).
Furthermore, these IgG2c stalk-reactive titers are largely lost in cKOs with no
compensatory increase in stalk-reactive IgG1 titers (Figure 5I). This indicates that
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the bulk of the HA stalk-specific antibody response requires T-bet-expressing B
cells.

39

Figure 5: Antibody Isotype, Titers, and Specificity Associated with B Cell
Specific T-bet Expression
(A and B) Total betapropiolactone (BPL)-inactivated PR8-specific IgG1 and
IgG2c (A) and PR8 hemagglutinin (HA)-specific IgG1 and IgG2c (B) in sera from
infected T-bet-ZsGreen mice over time. (C). Weight loss and recovery from
influenza infection in wild type C57Bl/6, CD19cre/WTT-betfl/fl, and CD19cre/WT mice
compared to PBS-treated controls. (D) Number of HA-specific splenic B cells at
day 15 and 40 post infection. (E) Number of HA-specific splenic germinal center
B (GCB) cells at 15 days post infection. (F) Hemagglutination inhibition (HAI)
titers at 15 and 40 days post infection. (G-I) Antibody titers to BPL-inactivated
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PR8 (G), full-length PR8-HA (H), or chimeric construct comprised of H1 stalk and
H6 head (I). Wild type C57Bl/6 were used for naïve controls in (F-I). Data are
represented as mean ± SEM from 3 independent experiments with at least 3-5
mice in each group. Statistical comparisons performed using two-sided t-test (GI) and Wilcoxon rank-sum test (F). *p<0.05, **p<0.01, ***p<0.001. Cells in (D, E)
were identified as DUMP-, CD19+, B220+, CD138-, IgD-, HA-PE+, with the
additional definition of germinal center B cells in (E) as PNA+CD95+. DUMP gate
includes CD4, CD8, Gr-1, and F4/80.
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2.4 Discussion
There are multiple outstanding questions regarding the role,
establishment, and characteristics of T-bet+ B cells in immune responses. In
order to address this, we undertook a detailed study of T-bet expressing B cells
following PR8 influenza infection. We found that T-bet expression can be used to
separate PR8 HA-specific B cells into three subsets. These populations differ in
multiple ways, including residency, effector function, and epitope specificity. At
early timepoints, both T-bet+ and T-bet- HA-specific B cells display a GC
phenotype and at later timepoints they assume a similar memory B cell fate. At
acute timepoints post-infection, HA-specific T-bet-, T-betlow, and T-bethigh B cells
can be observed in the responding secondary lymphoid tissues and the lungs.
While all three populations persist at similar relative frequencies in the spleen for
at least 100 days post infection, T-bethigh B cells largely disappear from the
lymphatics and lungs. Using parabiosis, we have demonstrated that HA-specific
T-bet- and T-betlow B cells recirculate between the spleens of the two partner
mice, but T-bethigh B cells are splenic residents that remain restricted to the
spleen of the previously infected partner. Furthermore, B cell specific T-bet
expression is required for most HA-specific IgG2c and HA stalk specific titers, as
mice lacking T-bet in B cells display a loss of these titers along with a failure to
maintain protective neutralizing HAI titers at memory timepoints. Together, this
shows that T-bet expression in B cells is an important determinant of populations
that differ in terms of recirculation, anatomic niche, isotype and specificity.
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We observed that HA-specific B cells appear in the spleen early following
PR8 influenza infection and undergo expansion followed by contraction and
maintenance regardless of T-bet expression. A fraction of these cells begin
displaying a GC phenotype as early as day 7 post infection as evidenced by
increased expression of GL7 and CD95 along with decreased CD38. This GC
phenotype peaks at days 15 and 22, as a large majority of T-bet+ and T-bet- HAspecific B cells express markers consistent with GC fate. Interestingly, T-bet
expression may be related to the timing of entry and exit from the GC as HAspecific T-bet+ B cells acquire and then lose a GC phenotype with faster kinetics
than their T-bet- counterparts. The significance of possible accelerated GC
kinetics in T-bet+ B cells remains unclear.
At later timepoints, a large portion of T-bet+ and T-bet- HA-specific B cells
express increased CD73. Higher levels of CD73 are suggestive of a GC origin for
most T-bet+ and T-bet- HA-specific memory B cells91, 92. However, BrdU pulse
labelling studies in an NP-CGG response have shown that a portion of memory B
cells arising prior to day 5 and before the establishment of a robust GC response
can also express elevated CD73. As such, expression of CD73 does not
necessarily indicate a GC origin112. Nevertheless, the CD73+ B cell population is
enriched for somatically mutated B cells as about 80% of CD73+ memory B cells
are somatically mutated as compared to only 30% of the CD73- population92. A
GC origin of T-bet+ memory B cells is consistent with prior findings showing that
T-bet+ B cell formation requires CD40/CD40L interactions and is associated with
a high incidence of somatic mutation47.
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Outstanding questions regarding the role of HA-specific B cells in recall
responses remain. Zuccarino-Catania et al. have demonstrated that memory B
cells can be stratified into populations with different recall functions based on
surface marker expression. In recall responses CD80+ PDL2+ memory B cells are
biased towards rapid plasma cell differentiation and limited GC recruitment
whereas CD80- PDL2- memory B cells participate in a robust GC response and
fail to generate many early plasma cells36. A series of elegant experiments by
Mesin et al. utilized a variety of approaches including clonal diversity and somatic
hypermutation analysis, fate-mapping, and parabiosis to demonstrate that there
is limited re-entry of germinal-center derived memory B cells into newly
generated GCs following a CGG-Alum boost. Rather, memory B cells that
participated in a GC following primary immunization are biased towards
plasmablast differentiation in the recall response37.Taken together, the fact that
the majority of HA-specific memory B cells in our studies expressed elevated
levels of CD80 and PDL2 along with a GC history, it seems likely that these HAspecific memory B cells would differentiate into antibody-secreting cells and fail
to re-enter the GC during secondary exposure to influenza. Additional studies are
required to confirm this hypothesis and to determine whether T-bet+ and T-betHA-specific B cells play differing roles in recall responses to influenza.
Our studies demonstrated unique anatomic compartmentalization
corresponding to T-bet expression, with both T-bet+ and T-bet- HA-specific B
cells present in the spleen, mediastinal LNs, lungs, and blood at early timepoints
post-influenza infection. While T-bet- B cells persisted in all these tissue
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compartments for at least 100 days post infection, T-bet+ B cells displayed
increasing splenic restriction with time. While the precise function and
mechanism of this tissue compartmentalization remains unclear, it may be tied to
differences in recirculation properties of T-bethigh, T-betlow, and T-bet- HA-specific
B cells. In parabiotic studies, T-bet- and T-betlow B cells are observed to
recirculate between the spleens of the two partner mice whereas T-bethigh B cells
remain restricted to the spleen of the previously infected partner. We posit that
the transient appearance of T-bethigh HA-specific B cells in the mediastinal LNs
and lungs early after infection may reflect extra-splenic generation of these cells.
Prior work from our lab has shown that intracellular nucleic acid sensing Toll-like
receptor stimulation together with Th1 type cytokines such as IFNγ can induce Tbet expression in B cells60. An inflammatory environment in the draining LNs or
lungs shortly after infection may be sufficient to transiently drive T-bet expression
in B cells at these sites. Consistent with this hypothesis, Barnett et al. observed a
strong enrichment of T-bet+ memory B cells in the small intestinal mucosa
following LCMV infection; a phenotype that was especially pronounced in the
intraepithelial lymphocytes with more than 65% of these B cells expressing Tbet51. The small intestinal mucosa, and in particular subepithelial CD11c+
dendritic cells, which reside in close proximity to intraepithelial lymphocytes,
represents a major site of Clone 13 LCMV viral infection113, 114. Chronic viremia,
immune activation, and inflammation may be sufficient to drive persistent T-bet
expression at extra-splenic sites. Pathogens such as HIV and Toxoplasma gondii
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which lead to persistent lymphoid tissue infections are associated with T-bethigh B
cells residing in the infected LNs115, 116.
Integrin and chemokine receptor expression in T-bet+ B cells may be an
additional important factor in the localization and recirculation properties of this
population. We have observed that a substantial portion of T-bethigh B cells
express the integrin CD11c. Work from the Wherry lab comparing gene
expression between T-bet+ and T-bet- B cells showed that CXCR3, a gene
involved in cell migration, was upregulated in T-bet+ B cells. They also confirmed
this upregulation via flow cytometry51. In human peripheral blood, T-bet+ B cells
express the integrin CD11c and the chemokine receptor CXCR3 along with low
levels of CXCR4, CXCR5, and CCR7 which are chemokine receptors associated
with homing to lymphoid organs49, 56, 71. Together, these surface receptors may
act to block lymphatic entry of T-bethigh B cells and help establish their splenic
residency. Intriguingly, we observed HA-specific T-bethigh B cells in the blood and
their peak incidence corresponded to the loss of T-bethigh HA-specific B cells from
the lungs and mediastinal LNs, consistent with their entry into the blood after
activation or recent tissue exit. In accordance with this, an increase in T-bethigh B
cells in human blood can be observed following influenza vaccination117.
In addition to their differences in localization and residency, T-bet+ and Tbet- B cells differ in terms of function. B cell specific T-bet knockout mice fail to
generate HA-specific IgG2c titers and show deficiencies in HA stalk specific
antibody production and a failure to maintain protective HAI titers. We posit that
T-bet+ and T-bet- B cells may have distinct roles following challenge with
46

heterologous strains of influenza. More specifically, T-bet+ B cells may be
important in sustaining sterilizing immunity against reinfection and in generating
broadly neutralizing HA stalk specific antibodies that could provide lasting
protection against a wide variety of strains. At both baseline and 28 days postvaccination, higher absolute IgG stalk specific influenza titers in humans are
associated with increasing age118. As T-bet+ ABCs accumulate with age, this
increase in stalk specific antibodies could be dependent on T-bet+ B cells along
with repeated exposure to divergent influenza strains. Additionally, T-bet+ B cells
can be observed at increased frequencies following influenza vaccination in
humans49, 117, 119. A major goal of current influenza research is the development
of an HA stalk reactive vaccine which could provide protection against a broad
range of divergent influenza strains and mitigate the need for annual
revaccination and redesign. Given the likely importance of T-bet+ B cells in
generating stalk specific antibodies and sustaining protective titers, developing
vaccination strategies that promote the generation and maintenance of HAspecific T-bet+ B cells is potentially a promising approach in the quest for a
universal influenza vaccine.
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CHAPTER 3: T-bet+ Memory B Cells are a Stable Population That
Contributes to Plasma Cell Pools
3.1 Summary
In this chapter, we focus on the stability and fate of T-bet+ B cells. We
show that T-bet expression in memory B cells is a durable state with T-bet+ and
T-bet- memory B cells comprising stable, independent populations. We observed
a trend of increasing CD138 expression with decreasing T-bet expression,
suggesting that circulating Tbetlow B cells may be losing T-bet on their way to
becoming plasma cells. In fact, a significant fraction of the plasma cell pool in
both the spleen and bone marrow is derived from T-bet expressing B cells, and
plasma cells can come from either T-bethigh or T-betlow precursors. Utilizing both
fate mapper adoptive transfer and parabiosis followed by separation surgery
techniques, we demonstrate that T-bethigh B cells give rise to T-betlow B cells but
not vice versa. Nonetheless, T-betlow B cells persist for a minimum of three weeks
in the absence of T-bethigh B cells.
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3.2 Introduction
The findings in the previous chapter resolve three memory B cell subsets
with differing anatomic distributions and specificities, but the relationships
between them, if any, is unclear. Moreover, because B cell-specific T-bet
expression is required for the bulk of HA-specific antibodies and sustained HAI
titers, we reasoned that T-bet+ subsets likely contribute to plasma cell pools.
Accordingly, we wanted to address whether there is frequent conversion between
T-bet+ and T-bet- B cells, and to explore the relationship between spleen-resident
T-bethigh B cells, recirculating T-betlow B cells, and plasma cells. We were
particularly interested in the ability of T-bet+ B cells to give rise to plasma cells
and to determine whether T-betlow B cells are a transition stage between T-bet+
memory B cells and T-bet- plasma cells.
Our prior results demonstrate that T-bethigh memory B cells are maintained
long term at stable numbers in the spleen. In conjunction with the tissue
residency of T-bethigh memory B cells, this suggests T-bet- and T-betlow B cells do
not continuously give rise to T-bethigh B cells, as this would preclude T-bethigh B
cells from being a uniquely splenic resident population. If T-betlow and T-betprecursors generated T-bethigh B cells, then we would have expected to find Tbethigh memory B cells in the spleens of both parabiotic partners. The
maintenance of T-bethigh populations at steady numbers suggests it is unlikely
that T-bethigh B cells simply lose T-bet expression as this would lead to
decreasing levels of T-bethigh B cells. However, it remains possible that T-bethigh
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B cells continually cycle with daughter cells leaving the T-bethigh pool to become
T-bet-.
In T cells, there is evidence that T-bet expression can be either a stable or
dynamic state. In Th1 T cells, T-bet expression is required and acts to prevent
the expression or function of transcription factors such as GATA-3 or RORγt
which are associated with the differentiation of Th2 or Th17 T cells45, 82, 86, 120, 121,
122

. Studies in T-bet fate mapping mice have shown that T-bet expression in

conventional CD4+ CD25- T cells is stable, as the majority of these fate mapped
cells maintain T-bet expression123.
On the other hand, regulatory T cells can express either T-bet or
GATA3124, 125, 126, 127, but it remained unclear whether these were two separate
subsets or if there was substantial interchange between these regulatory T cell
populations. Using T-bet fate mapper mice, Yu et al. showed that T-bet
expression in CD4+ CD25+ regulatory T cells is a dynamic state, as a large
portion of these fate mapped cells rapidly lost T-bet expression. This was
particularly pronounced in the LNs; over 60% of fate mapped CD4+ CD25+
regulatory T cells no longer expressed T-bet one week after tamoxifen
treatment123.
However, T-bet expression is not a simple on/off switch, as graded
expression of T-bet has important implications on cell fate decisions. In CD8 T
cells, the severity of inflammation and resultant IL-12 levels yield a gradient of Tbet expression, with higher IL-12 concentrations corresponding to increased T50

bet. The T-bet expression level influences cell fate decisions as low level T-bet
expression promotes memory precursor effector cell development whereas high
levels of T-bet drive the development of short lived effector cells128.
Dynamic control of transcription factors also drives cell fate decisions in B
cells. For example, IRF4 contributes to both GC B cell development and plasma
cell differentiation, despite these processes being regulated by mutually
antagonistic gene expression programs129, 130. IRF4 is thought to act in a “kinetic
control” fashion, as transient low level expression is required for GC B cell
development, whereas sustained high level expression leads to plasma cell
generation129.
Plasma cells and plasmablasts, collectively termed antibody secreting
cells (ASCs), are terminally differentiated B cells that secrete antibody. The
transition from B cell to antibody secreting cell involves extensive changes in
gene expression, morphology, and cellular lifespan and entails the loss of B cell
specific transcription factors and acquisition of plasma cell specific factors.
These B cell and plasma cell specific transcription factors control gene
expression networks that are mutually antagonistic resulting in a stable and
irreversible B cell to plasma cell transition131, 132.
T-bet expressing B cells may be important plasma cell precursors.
Following Ehrlichia muris infection, CD11c+ T-bet expressing IgM plasmablasts
are observed and likely give rise to long lasting bone marrow IgM plasma cells66,
133, 134

. Upon adoptive transfer followed by Ehrlichia muris reinfection , T-bet+ IgM

memory B cells give rise to CD138+ ASCs53. Additionally, T-bet+ B cells are
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required for the generation of long lived plasma cells and secondary ASCs
following initial influenza infection or re-challenge with a heterologous strain54.
In this chapter, we address the stability of T-bet+ B cells and examine their
fate using genetic fate-mapping mice. We show that T-bet+ memory B cells are a
stable population with limited interconversion into T-bet- B cell pools. However,
we observe an increase in plasma cell characteristics, specifically CD138
expression, that accompanies loss of T-bet expression, indicating that B cells
downregulating T-bet may be on their way to becoming plasma cells. Indeed,
both T-bethigh and T-betlow B cells give rise to plasma cells and T-bet expressing B
cells can generate both B220+ and B220- plasma cells. Additionally, T-bethigh B
cells give rise to T-betlow B cells. However, T-betlow B cells can be maintained
independently from T-bethigh B cells for a minimum of three weeks.
3.3 Results
3.3.1 T-bet+ and Tbet- memory B cells are stable, independent populations
We wanted to determine whether T-bet+ and T-bet- memory B cells
frequently interconvert or if they are maintained as separate B cell populations. In
order to explore this question, we used a Tg (Tbx21-ZsGreen,-cre/ERT2)H3Jfz
reporter/inducible cre transgenic mouse line123 bred to the
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze conditional reporter allele background135. This
yielded a combined T-bet reporter/fate mapper mouse (hereafter referred to as
fate mapper). This mouse is T-bet sufficient and expresses the ZsGreen
construct fused to creERT2 under the control of the T-bet promoter on a bacterial
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artificial chromosome. In these mice, treatment with tamoxifen during active T-bet
transcription causes irreversible TD Tomato expression, and active T-bet
expression is associated with ZsGreen florescence123.
Together, these two florescent markers delineate four cell populations; [1]
cells that are not currently expressing T-bet and did not express T-bet at the time
of tamoxifen administration (ZsGreen- TD Tomato-), [2] cells that expressed Tbet at the time of tamoxifen administration and continue to express T-bet
(ZsGreen+ TD Tomato+), [3] cells that expressed T-bet at the time of tamoxifen
administration but no longer express T-bet (ZsGreen- TD Tomato+), and [4] cells
that currently express T-bet but did not express T-bet at time of tamoxifen
administration (ZsGreen+ TD Tomato-) (Figure 6A). By administering tamoxifen
and performing longitudinal bleeds on the treated mice, we can track the
persistence of T-bet expression with time by monitoring changes in the relative
frequency of cells that retain T-bet expression (ZsGreen+ TD Tomato+) and cells
that expressed T-bet during the treatment period but have subsequently lost
expression (ZsGreen- TD Tomato+). We reasoned that if substantial conversion
from the T-bet+ to the T-bet- B cell pool occurs, then there should be significant
numbers of B cells that lose T-bet expression after being marked during
tamoxifen treatment.
We treated ≥ 20-week-old fate mapper mice with tamoxifen on days 0, 2,
and 4 and performed a series of longitudinal bleeds. All mice displayed TD
Tomato labelled CD3- CD19+ B cells by day 10 post tamoxifen treatment, and Tbet ZsGreen+ B cells outnumbered T-bet ZsGreen- B cells in the TD Tomato+
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population, often by a ratio of greater than 10:1 (Figure 6B). Importantly, the ratio
of T-bet ZsGreen+ to T-bet ZsGreen- cells in the TD Tomato+ B cell population
was maintained steadily with time in all mice (Figure 6B), suggesting that most B
cells expressing T-bet at day 0 maintained T-bet expression for at least 40 days.
We next wanted to explore T-bet persistence in memory B cells. In both
humans and mice, most antigen-experienced B cells downregulate surface IgD
expression upon transitioning towards memory B cell or plasma cell fate136, 137,
138, 139, 140, 141

. As such, we focused our analysis of T-bet persistence in tamoxifen

treated fate mapper mice on IgD- B cells. Similar to total B cells, CD3- CD19+ IgDB cells displayed evidence of TD Tomato fate mapping by day 10 post-tamoxifen
treatment and the majority of these TD Tomato+ fate mapped IgD- B cells
continued to express T-bet as evidenced by ZsGreen florescence (Figure 6C).
Furthermore, there was no evidence of increasing T-bet loss with time in our
sequential bleeds (Figure 6C), indicating that once T-bet expression is
established it is stably maintained for a minimum of 40 days.
While the majority of fate mapped IgD- B cells maintain T-bet expression,
there are low numbers of fate mapped cells that have lost T-bet. Plasma cells are
a terminally differentiated B cell fate and as such we wanted to determine
whether cells that have lost T-bet expression remain memory B cells or are
transitioning towards a plasma cell fate. In fate mapped IgD- B cells that lost Tbet ZsGreen florescence, there is an increased level of CD138 expression as
compared to fate mapped cells that maintained T-bet ZsGreen, indicating that
these cells may be differentiating into plasma cells rather than being maintained
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as T-bet- memory B cells (Figure 6D). This, along with sequencing data from our
lab showing limited clonal overlap between T-bet+ and T-bet- HA-specific memory
B cells in both mice and humans, suggests that T-bet expressing memory B cells
represent a stable B cell pool with limited interconversion into the T-bet- B cell
pool.
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Figure 6: T-bet+ and T-bet- memory B cells are a stable, independent
populations
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T-bet Fate Mapping mice123 were treated with three doses of tamoxifen (Tam) to
mark T-bet expressing cells with permanent, Rosa21-driven, tdTomato
expression (A) and the status of T-bet expression of marked CD3- CD19+ (B) or
CD3- CD19+ IgD- (C) B cells in the blood was tracked over 40 days. (D)
Histogram of CD138 expression in TD Tomato+ (fate mapped) IgD- T-bet
ZsGreen- (purple) or T-bet ZsGreen+ (blue) B cells a minimum of 40 days after
tamoxifen treatment. Four independent experiments were carried out with an
average of at least 3 mice per group; one representative experiment is shown
here.
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3.3.2 T-bet expressing B cells give rise to plasma cells
In the previous section, we established that T-bet+ B cells are a stable,
independent population and that the limited number of fate mapped cells that
have lost T-bet expression have increased levels of CD138 and may be
becoming plasma cells. In order to further address the correlation between loss
of T-bet and gain in plasma cell characteristics, specifically CD138, we treated
fate mapper mice with three doses of tamoxifen and waited for 40+ days. We
then gated on live, CD19+, B220+, dump-, IgD-, IgM- switched splenocytes (Figure
7A). Within this population, we analyzed CD138 expression in TD Tomato+ cells
expressing varying levels of T-bet ZsGreen (Figure 7B). As we gated on cells
positive for TD Tomato expression, we analyzed cell populations expressing Tbet at the time of tamoxifen administration 40+ days prior. We observed a clear
trend of increasing CD138 expression with decreasing levels of ZsGreen (Figure
7B). Thus, loss of T-bet expression is likely associated with a gain in plasma cell
character.
As increasing CD138 correlates with loss of T-bet expression, we wanted
to further explore the ability of T-bet+ B cells to give rise to plasma cells. Prior
work has shown that T-bet+ B cells can give rise to various cell types upon
transfer and re-challenge, including plasmablasts and memory B cells53, but it
remains unclear what happens to these T-bet expressing B cells in the absence
of re-challenge. In order to address this question, we again utilized T-bet fate
mapper mice.
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Fate mapper mice were treated with tamoxifen every other day for a total
of three doses and maintained for a minimum of 40 days post-treatment.
Following euthanasia, the spleen and bone marrow were analyzed for the
presence of CD138+ plasma cells and the fraction of these cells expressing TD
Tomato, indicating that they had been T-bet+ at the time of tamoxifen
administration, was analyzed (Figure 8 A-D). We observed that on average
greater than 16% of total splenic plasma cells were TD Tomato+, indicating that
T-bet expressing B cells robustly give rise to CD138+ plasma cells (Figure 8C).
TD Tomato+ CD138+ plasma cells were also present in the bone marrow, albeit
at lower proportions, averaging around 7% of total bone marrow plasma cells
(Figure 8D).
Since B220 expression can be used to stratify plasma cells into a primarily
long lived B220- population and a largely short lived B220+ pool142, we decided to
analyze the portion of plasma cells that were TD Tomato+ in each population
(Figure 8B). While TD Tomato+ plasma cells were seen in both the B220+ and
B220- plasma cell pools, a higher portion of B220+ plasma cells were TD
Tomato+ as compared to B220- plasma cells in both the spleen and bone marrow
(Figure 8C-D). This disparity was particularly evident in the bone marrow were
there was a nearly 10-fold enrichment in the proportion of plasma cells that
expressed TD Tomato in the B220+ versus B220- pools (Figure 8D). However, it
remains to be seen whether fate mapped B cells give rise to higher proportions of
B220- plasma cells at later timepoints following tamoxifen treatment.
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We directly assessed the turnover of TD Tomato+ plasma cells using BrdU
labelling in the tamoxifen-treated fate mappers. As before, fate mapper mice
were administered tamoxifen every other day for a total of three doses. Forty
days after tamoxifen treatment, mice were placed on continuous BrdU treatment
for either 13 or 20 days and the portion of B220+ and B220- plasma cells that
were positive for BrdU was analyzed (Figure 8 E-F). In both TD Tomato+ and TD
Tomato- plasma cells, a greater portion of B220+ as compared to B220- plasma
cells had incorporated BrdU. In TD Tomato+ B220+ plasma cells, roughly 70%
had incorporated BrdU whereas only around 20% of TD Tomato+ B220- plasma
cells were positive for BrdU (Figure 8 E-F). This is consistent with prior results
showing that B220+ plasma cells are a largely short lived population whereas
B220- plasma cells represent a primarily long lived ASC pool142.
As T-bethigh and T-betlow B cells have different tissue residency properties,
we wanted to determine if T-betlow B cells were the plasma cell progenitor
population or if T-bethigh B cells could give rise to plasma cells. This will help
determine whether plasma cells arise from a continuously recirculating T-betlow
population which could provide tissue surveillance for reinfection or if they are
derived from a splenic resident T-bethigh population. In order to evaluate this, we
utilized an adoptive transfer technique. We sorted splenic T-bethigh or T-betlow IgDB cells following CD4, CD8, Ter119, F4/80, and Gr1 magnetic depletion from fate
mapper mice treated 40+ days ago with tamoxifen. We then injected the sorted
cells retro-orbitally into separate B6.SJL congenic donors. We waited a minimum
of three weeks prior to sacrificing the recipient mice and analyzed live, dump-, TD
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Tomato+, CD45.2+ adoptively transferred CD19+ B cells and CD138+ plasma cells
derived from T-bethigh or T-betlow transferred memory B cells in order to determine
what populations give rise to plasma cells (Figure 9A-C). As TD Tomato+ B cells
were expressing T-bet at the time of tamoxifen administration 40+ days prior to
sorting and adoptive transfer, we used TD Tomato positivity as a surrogate
marker for memory B cells.
Despite the low number of recovered cells, we observed donor derived
CD138+ plasma cells in mice receiving either T-bethigh of T-betlow B cells (Figure
9D). Thus, both T-bethigh and T-betlow B cells can serve as progenitors for plasma
cells with increasing plasma cell characteristics acquired with loss of T-bet in
memory B cells.
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Figure 7: Increasing CD138 with loss of T-bet ZsGreen in fate mapped B
cells and plasma cells
(A) Pregating strategy for the analysis of CD138 expression in class switched B
cells in tamoxifen treated fate mapper mice. (B) Overlay flow plots showing
CD138 expression in TD Tomato+ fate mapped T-bethigh (purple), T-betlow (blue),
and T-bet- (orange) B cells. DUMP gate includes CD4, CD8, Gr-1, and F4/80.
Data displayed are representative of three independent experiments with a
minimum of three mice each.
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Figure 8: T-bet+ B cells give rise to B220+ and B220- plasma cells
(A) Pregating strategy for the identification of plasma cells (PCs) in tamoxifen
treated fate mapper mice. (B) Stratification of plasma cell populations by B220
staining and identification of the TD Tomato+ fate mapped fraction. (C and D)
Proportions of plasma cell populations in the spleen (C) and bone marrow (D)
that are TD Tomato+ (fate mapped). (E) Representative histogram showing BrdU
labelling in plasma cell populations. (F) Proportions of plasma cell populations
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that are BrdU+ after various periods of BrdU administration. DUMP gate includes
CD4, CD8, Gr-1, and F4/80. Data in (C) and (D) show individual points with the
mean ± SD indicated. Data in (A), (B), (C), and (D) are representative of or
compiled from a minimum of three independent experiments with a minimum of
three mice each. Data in (E) and (F) are representative of or compiled from two
independent experiments with two mice each (Day 13) or one experiment with 3
mice (Day 20). Statistical comparisons performed using paired two-tailed t-test.
**p<0.01, ****p<0.001
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Figure 9: T-bethigh and T-betlow B cells give rise to plasma cells
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(A) Experimental design for fate mapper T-bethigh and T-betlow adoptive transfer
studies. (B) Sorting strategy for T-bethigh and T-betlow B cells from tamoxifen
treated fate mapper donor mice. (C) Gating scheme for the identification of TD
Tomato+ fate mapped donor derived CD45.2+ B cells and plasma cells in B6.SJL
adoptive transfer recipients. (D) Overlay flow plots showing CD138 and T-bet
ZsGreen expression in TD Tomato+ fate mapped donor derived CD45.2+ B cells
and plasma cells recovered from B6.SJL recipients receiving either T-bethigh (red)
or T-betlow (blue) sorted donor cells. DUMP gate includes CD4, CD8, Gr-1, and
F4/80. Data displayed are representative of 3 recipient groups across two
independent experiments.
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3.3.3 T-bethigh memory B cells give rise to T-betlow memory B cells that persist for
a minimum of three weeks in the absence of a T-bethigh progenitor pool
Since both T-bethigh and T-betlow B cells give rise to plasma cells, we
wanted to further explore the relationship between these B cell populations. In
order to evaluate this, we once again utilized an adoptive transfer approach. In
brief, we treated fate mapper mice with three doses of tamoxifen and waited 40+
days after which we sorted splenic T-bethigh or T-betlow IgD- B cells following CD4,
CD8, Ter119, F4/80, and Gr1 magnetic depletion (Figure 9A-B). We then injected
these cells retro-orbitally into separate B6.SJL congenic donors and waited for a
minimum of three weeks prior to analyzing transferred live, dump-, TD Tomato+,
CD45.2+ memory B cells in the spleen of the recipient mice (Figure 10A).
We observed that adoptively transferred TD Tomato+ T-bethigh B cells gave
rise to T-betlow B cells whereas TD Tomato+ T-betlow B cells failed to become Tbethigh B cells (Figure 10B). This indicates that, unlike the total T-bet+ and T-betmemory B cell pools which are maintained as separate populations with limited
interconversion, there is substantial transit from the spleen resident T-bethigh into
the circulating T-betlow memory B cell pool. This does not occur in the reverse
direction, as T-betlow memory B cells do not give rise to T-bethigh memory B cells.
Based on our data showing that T-bethigh memory B cells can give rise to
T-betlow B cells, we wanted to address whether T-betlow B cells can be maintained
as a stable population or if they represent a transient population continuously
seeded from T-bethigh B cells. Utilizing our adoptive transfer results, we observed
that TD Tomato+ T-betlow B cells were still present three weeks after transfer
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(Figure 10B). This indicates that T-betlow memory B cells can persist for a
minimum of three weeks in the absence of a T-bethigh feeder pool and do not
require T-bethigh B cells for their continued maintenance. Future studies will be
required to evaluate the sustained presence of T-betlow memory B cells in the
absence of T-bethigh memory B cells at later timepoints.
As another means of assessing the persistence of T-betlow memory B cells
in the absence of a T-bethigh population, we separated parabiosied partners and
tracked circulating memory B cell subsets in the uninfected B6.SJL partner
(Figure 11A). In our earlier work, we demonstrated that by 17 days postparabiosis the mice had established a shared circulatory system and that HAspecific T-bet- and T-betlow B cells recirculated and could be found in the spleens
of both partner mice (Figure 4B-G). Importantly, T-bethigh HA-specific B cells were
restricted to the spleen of the previously infected partner and were absent from
the congenic B6.SJL partner (Figure 4D-G). While the previously infected partner
has all three HA-specific memory B cell subsets, the B6.SJL congenic partner
lacks the T-bethigh HA-specific B cell pool, allowing us to determine whether
maintenance of the T-betlow memory B cell pool requires a T-bethigh progenitor
pool. If the T-betlow B cell pool was short-lived and required continuous seeding
from T-bethigh progenitors, T-betlow B cells would not be sustained once isolated
from T-bethigh B cells. Therefore, we euthanized the mice after being separated
for a minimum of three weeks and analyzed the HA-specific memory B cell pools
in both partner mice.
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As expected, IgD- HA-specific B cells were observed in both partner mice
and the vast majority of these HA-specific B cells were CD45.2+ (Figure 11B),
indicative of their origin in the previously infected T-bet ZsGreen partner. The
HA-specific T-bethigh population was only observed in the previously infected
ZsGreen partner and was absent in the uninfected B6.SJL partner while HAspecific T-bet- B cells were observed in both partner mice (Figure 11C-E).
Importantly, we were able to detect an appreciable HA-specific T-betlow
population in both the B6.SJL and T-bet ZsGreen partners (Figure 11C-E). This
indicates that T-betlow B cells are maintained independently from T-bethigh B cells
for a minimum of three weeks, as HA-specific T-bethigh B cells were absent from
the B6.SJL partner and unable to contribute to the maintenance of the T-betlow B
cell pool. It is possible that the frequency of HA-specific T-betlow B cells may be
decreasing in the absence of a T-bethigh seeder population, indicating that over a
longer timeframe this T-betlow population may be lost in the absence of a T-bethigh
progenitor pool. These data together with our adoptive transfer results
demonstrates that while T-betlow memory B cells can be generated from T-bethigh
precursors, T-betlow memory B cells do not require T-bethigh progenitors for their
continued maintenance for a minimum of three weeks. Thus, T-betlow B cells may
represent a self-renewing population which can be maintained in the absence of
continued contribution from a T-bethigh B cell pool.
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Figure 10: T-bethigh B cells give rise to T-betlow B cells that persist in the
Transferred T-bet–tdTomato+CD138int

absence of a T-bethigh feeder pool for a minimum of three weeks
(A) Gating scheme for the identification of TD Tomato+ fate mapped donor
derived CD45.2+ B cells in B6.SJL adoptive transfer recipients. (B) Overlay flow
plots showing TD Tomato+ fate mapped donor derived CD45.2+ B cells recovered
from B6.SJL recipients receiving either T-bethigh (red) or T-betlow (blue) sorted
donor cells. DUMP gate includes CD4, CD8, Gr-1, and F4/80. Data displayed are
Transferred T-bet tdTomato CD38
representative of 3 recipient groups across two independent experiments.
–
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Figure 11: Independent maintenance of T-betlow memory B cells as
demonstrated by parabiont separation
(A) Experimental design for parabiosis followed by separation surgery studies.
(B) Gating scheme for the identification of T-bet-ZsGreen derived CD45.2+ HA+ B
cells in T-bet ZsGreen (top) and B6.SJL (bottom) separated parabionts. (C)
Subsetting of HA+ CD45.2+ B cells into T-bet-, T-betlow, and T-bethigh populations
via flow cytometry in T-bet ZsGreen (left) and B6.SJL (right) separated
parabionts. (D) Numbers of T-bet-, T-betlow, and T-bethigh HA+ splenic memory B
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cells (MBCs) per 106 CD45.2+ B cells in T-bet-ZsGreen (left) and B6.SJL (right)
separated parabionts. (E) Numbers of T-bet-, T-betlow, and T-bethigh HA+ splenic
memory B cells in T-bet-ZsGreen (left) and B6.SJL (right) separated parabionts.
DUMP gate includes CD4, CD8, Gr-1, and F4/80. Data in (D) and (E) show
individual points with the mean ± SD indicated. Data displayed are representative
of or compiled from 3 separated pairs across two independent experiments.
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3.4 Discussion
These studies investigate the stability and fate of T-bet expressing B cells.
Using T-bet fate mapper mice, we demonstrated that T-bet+ B cells are a stable
population with limited conversion into the T-bet- B cell pool. In fate mapped
memory B cells, increasing CD138 expression corresponds with lower T-bet
levels, indicating that a decrease in T-bet expression in B cells may be
associated with a gain in plasma cell characteristics. Indeed, a substantial portion
of both splenic and bone marrow plasma cells, especially in the B220+ plasma
cell population, are derived from T-bet expressing B cells despite only a brief
window of tamoxifen treatment, and both T-bethigh and T-betlow B cells can give
rise to plasma cells. Additionally, T-bethigh B cells give rise to T-betlow B cells, but
T-betlow B cells do not upregulate T-bet in order to enter the T-bethigh B cell pool.
Nevertheless, T-betlow memory B cells can be maintained in the absence of a Tbethigh B cell pool for a minimum of three weeks, indicating that T-betlow B cells
may represent a self-renewing population that can be maintained in the absence
of T-bethigh B cells. Taken together, these findings demonstrate that T-bet+
memory B cells give rise to plasma cells, and that T-bethigh B cells can contribute
to both the T-betlow B cell pool and plasma cell populations.
While our prior results demonstrated that both T-bet+ and T-bet- memory B
cells are generated and sustained long term in the spleen following PR8
influenza infection and that T-bet+ B cells are important for IgG2c and stalkspecific antibody responses as well as sustained protective HAI titers, it
remained unclear whether there was substantial ongoing exchange between T73

bet+ and T-bet- B cell pools. Our fate mapper results demonstrate the absence of
sustained entry of T-bet+ B cells into the T-bet- B cell pool, indicating that T-bet+
and T-bet- B cells are maintained as separate populations.
There are remaining questions regarding the role of T-bet+ and T-bet- B
cells, particularly in recall responses to mutating pathogens as seen with immune
imprinting or original antigenic sin (OAS). Infective pathogens, particularly rapidly
mutating viruses, can undergo antigenic variation wherein mutations lead to
alterations in surface antigens, subverting high affinity recognition by previously
generated antibodies. In the case of influenza, antigenic drift can lead to frequent
changes in antigenically important sites which can drastically impair antibody
recognition and immune protection143. During subsequent exposure to the
antigenically drifted pathogen, the antibody response is biased towards the
previously encountered strain which impairs the response to the current infecting
strain144. The concept of OAS has striking similarities to carrier-mediated hapten
suppression wherein prior exposure to a carrier protein leads to suppression of
the hapten antibody response during subsequent hapten-carrier immunization145.
Additional work has shown that carrier-mediated hapten suppression has a
particularly strong effect on blocking hapten specific IgG2a/c responses during
the secondary hapten-carrier immunization146. As class switching to the IgG2a/c
isotype is strongly associated with T-bet expression40, 42, 100, T-bet+ B cells may
play an important role in carrier-mediated hapten suppression and OAS. Indeed,
in carrier-mediated hapten suppression, the Th1 type response is largely
absent147. As B cell specific T-bet expression requires a Th1 type cytokine
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environment60, lack of a Th1 type response likely impairs the T-bet+ B cell
response. OAS can be subverted in a murine heterologous influenza challenge
model if adjuvants that induce a Th1 type response are added to the vaccination
regimen148, implying that the lack of Th1 type cytokines and T-bet+ B cells may
play a key role in OAS and carrier-mediated hapten suppression. As such,
properly regulating the recruitment of T-bet+ memory B cells during vaccination
and re-challenge may be an important way to avoid OAS and provide optimal
sustained protection against rapidly mutating pathogens. Specifically, inducing a
Th1 type environment may help recruit memory T-bet+ B cells or generate new Tbet+ B cells in the recall response and allow subversion of OAS.
We have shown that loss of T-bet correlates with increasing CD138 levels
and that T-bet+ B cells are able to generate plasma cells. This prompts questions
regarding the potential role of T-bet expression in controlling antibody-secreting
cell differentiation. Stone et al. have demonstrated that suppression of IFNγ
mediated inflammatory effects on B cells via T-bet expression is likely important
in promoting plasma cell differentiation, in particular in recall responses54.
Additionally, B cell intrinsic T-bet is required for IgG2a/c plasma cell
differentiation, likely via STAT1100. As rising levels of CD138 are observed with
decreasing T-bet, it is possible that CD138 itself may function to help assure
plasma cell differentiation and survival upon the progressive loss of T-bet.
Notably, Blimp1 can antagonize T-bet expression149 and plasma cells with higher
levels of Blimp1 had decreased expression of the majority of T-bet target genes
75

assessed100, implying a possible link between increasing plasma cell
differentiation and decreasing T-bet levels. CD138 likely acts in a cell intrinsic
manner to promote plasma cell accumulation and survival in vivo. Cell surface
CD138 expression increases heparan sulfate levels on plasma cells and this
leads to increased binding of pro-survival cytokines such as IL-6 and APRIL and
increased plasma cell survival150. T-bet mediated suppression of IFNγ induced
inflammation may no longer be required for survival and plasma cell
differentiation upon increased expression of CD138.
While both T-bethigh and T-betlow B cells give rise to plasma cells, there are
important differences between these cell populations warranting further
investigation of the relationship between these B cell pools. Our prior results
demonstrated that T-bethigh and T-betlow B cells differ in their recirculation
capacity, as T-bethigh HA-specific memory B cells are splenic resident whereas Tbetlow memory B cells recirculate between parabiotic partners. While it is tempting
to speculate that circulating T-betlow B cells are a transient population derived
from stationary, self-renewing T-bethigh B cells on their way to becoming T-betplasma cells, the situation is likely more complex. T-betlow B cells can be
maintained in the absence of a T-bethigh population for a minimum of three
weeks. Thus, a portion of T-betlow B cells are a stable and persistent population
that may have separate maintenance and induction requirements from the Tbethigh subset. These two possibilities are not mutually exclusive as the T-betlow B
cell population may contain both a stable and a transient component.
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It will be of interest to determine the role of T-bethigh and T-betlow B cells in
a recall response, as both populations give rise to plasma cells. Future studies
exploring whether T-bethigh and T-betlow B cells have different requirements for
their induction and maintenance are warranted. One possibility is that T-bethigh B
cells may require a splenic niche for their generation whereas T-betlow B cells
may be able to be generated at alternative sites such as reactive LNs.
Splenectomy followed by infection and subsequent evaluation of B cell
populations at early time points may help in resolving this question.
As T-bethigh B cells are maintained long term at stable numbers while also
giving rise to T-betlow B cells and plasma cells, we posit that T-bethigh memory B
cells may have a stem like nature. Indeed, Kenderes et al. have demonstrated
that T-bet+ IgM memory B cells generated following Ehrlichia muris infection can
both self-renew and generate multiple lineages of effector B cells following rechallenge, demonstrating their stem-like nature53. Our studies extend these
findings by establishing the presence of both T-bethigh and T-betlow memory B
cells and showing that T-bet+ B cells continue to generate plasma cells in the
absence of re-challenge. Future studies such as rapamycin treatment or
sublethal irradiation to further explore the stem-like nature of T-bethigh B cells are
of interest.
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CHAPTER 4: Conclusions, Implications, and Future Directions
We have undertaken a detailed investigation of T-bet+ B cells including
their emergence, maintenance, and role in a murine influenza infection model,
their stability, and their ability to give rise to antibody secreting cells. As T-bet
expressing B cells are important in the control of a variety of infectious diseases
and contribute to autoimmunity in both mice and humans, a better understanding
of the requirements for the emergence and maintenance of this population along
with their terminal differentiation fate could help inform more effective
prophylactic vaccines and treatments for autoimmune pathologies.
In chapter two, we have shown that following PR8 influenza infection in
mice, T-bet+ HA-specific B cells emerge in the spleen, lungs, and draining
mediastinal LNs at acute timepoints. At memory timepoints, T-bet+ HA-specific B
cells become progressively restricted to the spleen, despite the continued
presence of T-bet- HA-specific B cells at other anatomical sites. Both T-bet+ and
T-bet- HA-specific B cells first display a GC phenotype before transitioning to a
CD73+ CD80+ PD-L2+ memory phenotype. T-bet+ B cells can be further subset
into T-bethigh and T-betlow B cells, with T-bethigh HA-specific B cells being a spleen
resident population as evidenced by parabiosis studies. Furthermore, T-bet
expression in B cells is required for HA-specific IgG2c titers and sustained
protective HAI titers. Additionally, stalk specific influenza antibodies are largely
ablated in the absence of T-bet expressing B cells (Figure 12).
In chapter 3, we utilized fate mappers to demonstrate that most T-bet
expressing B cells maintain their T-bet positivity and are a stable, separate
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population from T-bet- B cells. We also showed that T-bet+ B cells differentiate
into plasma cells: downregulation of T-bet is associated with a gain in plasma cell
characteristics, as evidenced by increasing CD138 expression, and a portion of
plasma cells in both the bone marrow and spleen are derived from T-bet
expressing B cells. Notably, T-bet+ B cells are especially apt at producing B220+
plasma cells. We further demonstrated that T-bethigh B cells can give rise to Tbetlow B cells as well as plasma cells. However, T-betlow B cells can still be
maintained independently of T-bethigh B cells for a minimum of three weeks
(Figure 12).
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Figure 12: Residency, function, and fate of T-bet expressing B cells
Following PR8 influenza infection, T-bet-, T-betlow, and T-bethigh memory B cells
are established and maintained long term. While T-bet- and T-betlow memory B
cells recirculate, T-bethigh memory B cells are restricted to the spleen and are
resident. T-bet+ B cells are required to establish hemagglutinin stalk specific
antibody titers. While T-bethigh B cells can give rise to T-betlow B cells, T-betlow B
cells fail to become T-bethigh. Furthermore, the T-bet+ B cell pool is maintained as
a stable, separate population from the T-bet- B cell population. Both T-bethigh and
T-betlow B cells can give rise to B220+ and B220- plasma cells with increasing
CD138 expression corresponding with decreasing T-bet levels.
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These studies suggest that the T-bet expressing B cell population
constitutively generates plasma cells at a basal rate. While this may reflect
antigenic stimulation from self-antigens or antigens endogenous to our colony,
the magnitude of plasma cell differentiation observed raises alternative
possibilities. We postulate that there may be continuous differentiation of T-bet+
B cells into plasma cells, potentially in an antigen-independent manner,
functioning to support maintenance of neutralizing antibody titers at levels
sufficient to provide sterilizing immunity.
While the classic view of immune memory emphasizes the effectiveness
of antigen specific memory lymphocytes in mounting a rapid secondary
response, protective immune memory relies heavily on maintenance of protective
antibody titers. In fact, vaccination is often aimed at eliciting sufficient protective
titers to maintain sterilizing immunity long term, even in the absence of persistent
antigen151. This is particularly important in providing protection against toxins,
where pathology may be too rapid to allow the generation of a secondary
response to be effective152. In clinical veterinary medicine, the importance of
protective antibody titers can be seen in the management of newborn animals.
Assuring that newborn cattle rapidly get appropriate, high quality colostrum in
order to allow passive transfer of maternal antibodies is considered the most
important management factor in assuring calf survival153. Up to 31% of calf
mortality events in the first 21 days of life can be attributed to failure of passive
transfer154. Furthermore, passive immunization in the form of antibody transfer
has been used clinically since the 19th century. The importance of passive
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immunization and neutralizing antibodies can be seen in the treatment and
prevention of diphtheria, where Behring’s discovery of the use of immune serum
massively reduced morbidity and mortality. In fact, it was hailed by the Lancet as
the “most important advance of the century in the medical treatment of acute
infective disease”155. In Germany alone, diphtheria treatment via passive
immunization is credited with having saved as many as 45,000 lives per year156.
Appropriate maintenance of protective titers is essential for effective
immune protection and optimal health. While these lasting titers have often been
accredited to long-lived bone marrow plasma cells, recent work has shown that
newly formed, rapidly turning over plasma cells likely play a major role in long
term antibody titer maintenance142. These plasma cell subsets can be
distinguished on the basis of B220 expression as BrdU labelling studies have
demonstrated that B220- plasma cells are primarily long lived whereas B220+
plasma cells are largely short lived142. While our studies show that T-bet
expressing B cells can generate both B220+ and B220- plasma cells, a higher
portion of B220+ plasma cells are derived from T-bet expressing B cells as
compared to B220- plasma cells. Thus, we posit that T-bet+ memory B cells play
a key role in the maintenance of lasting protective titers by continuously
generating antibody secreting plasma cells.
Multiple lines of research support the importance of T-bet+ B cells in giving
rise to plasma cells that maintain antibody titers. Our work showed that mice
lacking B cell specific T-bet expression failed to sustain protective HAI titers long
term following PR8 influenza infection. Additionally, Kenderes et al. propose that
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T-bet+ IgM memory B cells generate ASCs following Ehrlichia muris infection53.
Influenza vaccine-generated CD21low B cells, which express increased levels of
T-bet mRNA and protein, are similarly poised for plasma cell differentiation as
they have elevated expression of plasma cell associated genes such as BLIMP149. Further, T-bet+ B cells isolated from lupus patient blood are able to rapidly
differentiate into plasma cells upon TLR7 and IL-21 stimulation in the absence of
cell division67, and lupus prone mice lacking T-bet+ B cells demonstrate reduced
autoantibody titers and kidney pathology, leading to improved survival57.
Interestingly, the memory marker profile observed on our HA-specific T-bet+ B
cells is also consistent with plasma cell differentiation as opposed to GC entry
following re-stimulation36, 37. A recent study by Stone et al. further demonstrates
the role played by T-bet-expressing B cells in plasma cell differentiation during
the influenza recall response to heterologous challenge, as inducible deletion of
T-bet in memory B cells causes an up to 10-fold reduction in levels of induced
total and IgG2c antigen-specific plasma cells. Interestingly, T-bet is not required
for the survival of T-bet+ memory B cells, but rather for plasma cell differentiation,
as memory B cell numbers are not impacted by inducible T-bet deletion. T-bet
mediated repression of an IFNγ dependent inflammatory gene program may be
important in promoting plasma cell differentiation54.
Assuming that T-bet+ B cells are continuously generating plasma cells,
regulation of this process is necessary to assure that appropriate numbers of
plasma cells and levels of antibody titers are maintained. One possibility is that
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this differentiation is regulated by circulating antibody levels. T-bet+ B cells may
detect a decrease in free circulating antibody, as could happen after re-exposure
to a pathogen due to formation of antigen-antibody complexes. This could induce
increased numbers of T-bet+ B cells to undergo plasma cell differentiation. In
support of such an idea, Kenderes et al. observed that T-bet+ IgM memory B
cells failed to differentiate into plasma cells in chronically infected mice that have
high titers of protective antibodies but most of these cells became plasma cells in
newly infected mice lacking pre-existing titers53. Multiple myeloma patients have
reduced levels of normal polyclonal serum immunoglobulins, likely due to a B cell
extrinsic mechanism which prevents B cells from differentiating into plasma
cells157; such a mechanism could be dependent on the high levels of monoclonal
antibodies arising from malignant plasma cells. Studies by Pape et al. further
support such a mechanism, as immune serum transfer decreased memory B cell
to plasma cell differentiation158. If such a mechanism is in play, we would expect
decreased levels of plasma cell generation from T-bet expressing B cells in the
presence of increased antibody levels. Conversely, plasma cell genesis from Tbet+ B cells would likely be increased in mice with lower total antibody titers.
While the mechanism is unclear, increased Fc receptor binding is a possible
candidate that may suppress this differentiation33, 159. Future studies to compare
the expression levels and types of Fc receptors on T-bet+ and T-bet- memory B
cells will be necessary to investigate this possibility.
Conversely, T-bet+ B cells may be induced to differentiate into plasma
cells in response to polyclonal activation. Such a situation is seen in human
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memory B cells that proliferate and differentiate into plasma cells following
activation with polyclonal stimuli such as CpG DNA or bystander T cell help160.
ABCs, a large fraction of which are T-bet+, show robust responses to innate
stimuli: as compared to follicular B cells, ABCs fail to respond to BCR
crosslinking and/or anti-CD40, but robustly proliferate in response to TLR9
stimulation as provided by CpG41.
An alternative possibility is that T-bet+ B cells may express broadly
reactive BCRs allowing them to be stimulated and differentiate into plasma cells
in response to a range of conserved antigenic determinants. Such ideas are not
unprecedented, as MZ B cells often express polyreactive BCRs that can bind to a
range of microbial molecular patterns. In addition, MZ B cells have high levels of
TLR expression and dual stimulation of the BCR and TLR can result in rapid
differentiation of this subset into antibody secreting plasma cells161. A similar
situation may be occurring with T-bet+ B cells, and indeed these B cells are
responsible for the antibody response to the conserved stalk epitopes in
influenza infection. It would be interesting to see if T-bet+ B cells are responsible
for the antibody response to other conserved antigenic determinants.
Importantly, these possibilities imply that T-bet+ B cell memory may have
innate-like characteristics, and this may help to explain the purpose for splenic
residency of T-bethigh memory B cells. Under this concept, T-bet+ B cells localized
to the spleen would function to rapidly detect circulating factors associated with
infection in order to quickly increase plasma cell genesis and protective antibody
titers. Much of the previous research on resident lymphocytes has been done on
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T cells, where parabiosis studies demonstrate that both CD4 and CD8 T cells
establish tissue resident memory (TRM) populations in various organs and barrier
sites26, 162, 163, 164. These TRM populations provide important and rapid protection
against a wide variety of local reinfections through various means including direct
effector functions and recruitment and activation of other immune cells30.
Hpwever, TRM can also be maladaptive and contribute to allergic or autoimmune
pathology165.
In terms of B cells, tissue resident memory is less appreciated. B cells
give rise to plasma cells, which secrete antibodies that freely recirculate, and as
such the importance of residency is less clear. Studies from Young et al.
comparing lymphocytes in the blood and lymph of sheep demonstrated that the
majority of non-recirculating peripheral blood lymphocytes were B cells. These
non-recirculating B cells lacked surface expression of CD21 and thus may
correspond to the CD21- CD23- T-bet+ ABC population observed in mice and
humans166. Furthermore, it may be important for B cells to persist at sites of
infection to allow rapid stimulation and differentiation into antibody secreting
plasma cells upon local reinfection. In fact, research from the Randall lab has
utilized parabiotic studies to demonstrate that lung resident memory B cells are
established following intranasal influenza infection and require local antigen
encounter for their generation. Upon local intranasal re-challenge, these lung
resident memory B cells rapidly give rise to antibody secreting plasmablasts
whereas recirculating memory B cells failed to contribute to this plasmablast
response97.
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While tissue residency in both B and T cells may be important in providing
surveillance and protection against local reinfection, this explanation seems less
likely for spleen resident HA-specific T-bethigh B cells. Influenza is a respiratory
infection and does not replicate in the spleen, making this an unlikely site for
reinfection167. However, the idea of resident memory cells in secondary lymphoid
organs is not unprecedented: resident CD4 T cells can be found in the cervical
and mesenteric LNs and peyers patches168, and parabiosis studies identify
antigen-specific resident CD8 T in the draining mediastinal LN more than a
month after influenza infection. This is likely related to the persistence of
processed viral antigens in the draining nodes, since CFSE labelled antigenspecific CD8 T cells show increased proliferation in the mediastinal LNs following
transfer into previously infected mice as much as 60 days after infection169.
Antigen persistence in the draining LNs may also explain the maintenance of
mediastinal LN-resident HA-specific T-bet- B cells that we observed in parabiosis
studies, as these displayed a GC phenotype as late as 100 days post influenza
infection.
While it is possible that antigen persists long term in the spleen following
influenza infection, this is unlikely to explain the splenic residency of T-bethigh
memory B cells for several reasons. First, only T-bethigh memory B cells were
splenic resident and T-bet- and T-betlow B cells were able to freely recirculate
between parabiotic partners. Additionally, there was no noticeable expansion of
HA-specific cells in the CD45.1 B cell fraction in the spleen of the previously
infected partner as would be expected in the case of persistent antigen. Further,
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splenic T-bet+ B cells’ loss of GC phenotype and transition to memory phenotype
by day 40 post infection suggests antigen is largely cleared. In support of
antigen-independent maintenance, parabiosis studies show that lymphocytes can
be resident in secondary lymphoid organs in the absence of persistent antigen:
resident LCMV-specific memory CD8 T cells can be found in the spleen and LNs
of LCMV Armstrong infected mice well after viral clearance, and CD69, which is
associated with tissue residency, is not upregulated until after viral clearance170.
Furthermore, the localization of resident memory lymphocytes within
secondary lymphoid organs is not random, and this may have important
functional implications for splenic resident T-bethigh memory B cells. Using a
combination of parabiosis and immunofluorescence microscopy, Schenkel et al.
showed that antigen specific CD8 memory T cells in the LNs of the previously
LCMV infected partner were largely localized to the LN sinus, whereas in the
uninfected partner these cells were primarily found in the T cell zone. Likewise,
these antigen specific CD8 T cells preferentially reside in the splenic MZ at the
expense of the white pulp in the previously infected parabiont170. Importantly, the
splenic MZ and LN subcapsular sinus are prime sites for a wide range of initial
microbial entry and antigen capture and presentation171, 172, 173, 174, 175. In
particular, the splenic MZ is specialized for blood borne antigen surveillance, with
a unique microarchitecture resulting in the slowing of blood flow to allow efficient
capture of antigens from the blood stream176. MZ macrophage antigen capture is
important for the proper control of certain infections, as mice lacking proper
antigen uptake in the MZ are impaired in their ability to control infection by
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pathogens such as Listeria monocytogenes or Streptococcus pneumoniae and
are more susceptible to death174, 177. MZ B cells are a largely resident population,
as demonstrated by their limited migration in parabiosis studies and numerical
persistence in the non-irradiated section of the partially irradiated spleen in
rats178, 179. This MZ retention is likely dependent on the interaction between
Sphingosine 1-phosphate receptor 1 (SIP1) and CXCL13, since MZ B cells are
displaced from the MZ into the splenic follicles in S1P1 deficient mice. In
S1P1/CXCL13 double deficient mice, normal MZ B cell localization is restored,
indicating that S1P1 functions to block CXCL13 mediated recruitment of MZ B
cells to the splenic follicles180.
In light of the importance of the MZ in antigen surveillance, it is tempting to
speculate that the splenic resident T-bethigh population observed after influenza
infection may be localized to the MZ. In such a case, these cells would be
uniquely positioned to support broad immune surveillance and rapidly detect
invading pathogens. Indeed, previous studies have shown that memory B cells
can be found in the MZ and perifollicular regions of the spleen181, 182, and much
of this localization is dependent on CCR6. In mice lacking CCR6, the frequency
of memory B cells in the perifollicular region is massively decreased, while their
frequency in follicular regions is increased more than 6-fold. However, the
frequency of memory B cells in the MZ is not significantly changed in CCR6
knockout mice. CCR6 may be important in recall responses as bone marrow and
splenic plasma cell numbers, along with serum titers, were reduced in the recall
response in CCR6 knockout mice. These CCR6 mediated effects on the
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secondary response are B cell intrinsic, as demonstrated by mixed bone marrow
chimera studies182. Future studies involving immunohistochemistry staining of
splenic sections will be required to determine the precise splenic localization of
T-bethigh B cells relative to their T-betlow and T-bet- counterparts. It will also be
important to determine differences in chemokine and cytokine receptor profiles
between these subsets and to determine how these contribute to localization and
recirculation properties. Assuming that splenic resident T-bethigh B cells are
preferentially localized to the splenic MZ, it is tempting to postulate that they are
poised to rapidly differentiate into antibody secreting cells and produce
antibodies for systemic dissemination following reinfection.
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CHAPTER 5: Materials and Methods
Mice: C57BL/6 and B6.SJL (10-12 weeks old, females, purchased from The
Jackson Laboratory); Tbx21F/F possessing loxP sites flanking exons 2-6 of
Tbx21183 and Cd19tm1(cre)Cgn containing a targeted cre cassette into exon 2 of
Cd19184 (obtained from the laboratory of E. John Wherry, University of
Pennsylvania); Tbx21-ZsGreen with a ZsGreen reporter gene inserted at the
Tbx21 start site in BAC RP23-237M1486; Tbx21-ZsGreencreERT2 possessing the
BAC RP23-237M14 with the ZsGreen reporter gene, T2A self-cleaving peptide,
and inducible creERT2 recombinase gene123; and Rosa26LSL/tdTomato with a
Rosa26 targeted construct containing CAG-LSL-tdTomato-WPRE135 were
maintained and used in accordance with the University of Pennsylvania
Institutional Animal Care and Use Committee guidelines.

Infections: Mice were infected by intranasal infection with 30 tissue culture
infectious dose50 (TCID50) of influenza strain A/Puerto Rico/8/1934 (PR8;
American Type Culture Collection).

Parabiosis and separation surgery: Age-matched T-bet ZsGreen reporters and
B6.SJL adult female mice were conjoined as described previously185. Briefly, a
skin incision was made from the olecranon to the knee of each of the mice to be
joined. The elbows and knees of the two paired mice were then tied together with
surgical suture, followed by connecting of the skin with surgical sutures and
staples. For pain control, mice were given buprenorphine (0.1 mg/kg every 6
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hours for 36 hours) and meloxicam (5 mg/kg every 12 hours for 72 hours) and
provided with sulfamexathole (400mg/L) and trimethoprim (800mg/L) antibiotics
in their drinking water to prevent infection. Mice were monitored for signs of pain,
infection, or damage to sutures. Blood was periodically drawn from the tail to
check for anastomoses, which appeared complete by day 14, therefore, mice
were euthanized at day 17. The spleen was harvested from both partners for all
pairs, and the lungs and mediastinal LNs were also collected from some pairs.
Seperation surgery was performed similar to parabiosis surgery except an
incision was made from the olecranon to the knee of the paired mice and the
joining suture was severed after which sutures were used to appose the dorsal
and ventral skin flaps in each partner. Mice were maintained for a minimum of
three weeks following separation surgery.

Flow cytometry: Flow cytometry reagents were purchased from BioLegend
(BL), BD Biosciences (BD), eBioscience (eBio), Southern Biotech (SB), or
Invitrogen (Inv). The following antibodies were used: CD11c (N418; BL), IgM
(R6-60.2; BD), CD38 (90; eBio), CD73 (TY/11.8; BL), CD80 (16-10A1; BD or BL),
PD-L2 (TY25; BL), CD138 (281-2; BL), IgD (11–26c.2a; BL), B220 (RA3-6B2; BL
or eBio), CD19 (1D3; BD or eBio), CD19 (6D5; BL) peanut agglutinin–FITC
(Sigma), CD45.1 (A20; BL), CD45.2 (104; BL), CD183/CXCR3 (CXCR3-173; BL)
and CD3 (17A2; BL). DUMP gate comprised CD8 (53-6.7; eBio), CD4 (H129.19;
BL), F4/80 (BM8; eBio), Ly-6G/GR1 (RB6-8C5; eBio). For detection of murine
influenza hemagglutinin binding B cells, recombinant HA PR8186 was obtained
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from the laboratory of Dr. Barney Graham, National Institute of Allergy and
Infectious Disease, biotinylated, and conjugated to streptavidin-fluorophores as
previously described186. Mouse samples were prepared for flow cytometry as
follows: Mouse Fc fragment (Jackson ImmunoResearch; 015-000-008) was
added to all staining cocktails at a final concentration of 1:200. Mouse spleens
were homogenized, on ice, in staining buffer (PBS + 0.5%BSA + 2mM EDTA)
and passed through nylon mesh (50μM) to obtain single cell suspension. Bone
marrow was flushed from the femur and tibia with staining buffer following
removal of muscles and and passed through nylon mesh (50μM). Red blood cells
were lysed using ACK lysing buffer (Lonza, cat 10-548E) as per manufacturer’s
instructions. Mouse LNs were homogenized, on ice, in staining buffer and passed
through nylon mesh (50μM). Cells were washed with PBS and stained as
described previously41, 60. Live/dead discrimination was done using Zombie Aqua
fixable viability kit (BL). Data were acquired on BD LSR II flow cytometer and
FACS analyses were performed using FlowJo v9 and v10 (Becton Dickinson Co.,
Ashland, OR).

Serum antibody titers: Serum was harvested by spinning whole blood at
13000g for 10 minutes and stored at -20°C until use. Antibody titers were
assessed using ELISA as previously described41, 60 with the following
modifications: 96-well medium-binding plates were coated with either 20HAU/well
of BPL-inactivated PR8, 2 μg/mL of PR8 HA, or 2 μg/mL of H6/H1 chimeric
constructs (expressed in baculovirus system as previously described187). HA93

specific monoclonal antibodies (from Dr. Jonathan Yewdell, National Institute of
Allergy and Infectious Diseases) were used as standards to determine
concentration of IgG1 and IgG2a/c. Standards were used at a starting
concentration of 100 ng/mL for IgG2a and 10 ng/mL for IgG1 and diluted 2-fold
across.

HAU (hemagglutination unit) and HAI assays: Viral HAU titers were
determined before every HAI assay. All dilutions were prepared in PBS. 50 μL
diluted virus, 50 μL diluted heat-inactivated sera and 12.5 μL of 2% turkey
erythrocytes were used per well for all assays, which were performed in roundbottom plates.
Starting with a 1:100 dilution of live virus, 2-fold dilutions were mixed with
2% turkey erythrocytes (Lampire biologicals) and incubated for 1 hour at room
temperature. Agglutination dose (AD) was determined at the end of the
incubation period, and confirmed by repeating the process with a 2-fold dilution
series of virus, ranging from 4AD to 0.25 AD. This dose was subsequently used
for the HAI assay.
Sera were heat-treated at 55°C for 30 minutes, diluted 2-fold in PBS
(staring dilution 1:20), mixed with 4AD and 2% turkey erythrocytes, and
incubated as for HAU assay. HAI titers are expressed as inverse of the highest
dilution that inhibited agglutination.
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Tamoxifen Treatment: Tamoxifen (Sigma; cat. T5648-1G) was dissolved in
100% ethanol to a concentration of 80 mg/ml and vortexed and heated at 42°C
until completely dissolved. An equal volume of Kolliphor (Sigma, cat. C5135500G) was added to bring the solution to a concentration of 40 mg/ml. Aliquots
were then stored at -20°C. Immediately prior to administration, tamoxifen aliquots
were thawed at 42°C and diluted with PBS to 8 mg/ml. Mice were administered
three doses of 0.8 mg of tamoxifen via intraperitoneal injection every other day.

Cell Sorting: Murine splenocytes were prepared as described prior then
negatively selected using a cocktail of biotinylated antibodies against CD4 (RM45, eBio), CD8a (53-6.7; eBio), F4/80 (BM8; eBio), Ly-6G/GR1 (RB6-8C5; BD),
and Ter-119 (Ter-119; BL). After washing with staining buffer, cells were
incubated with 100ul Streptavidin MicroBeads (Miltenyi Biotec) in 900ul staining
buffer for 30 min. Cells were then washed and ran through a negative selection
LD column (Miltenyi Biotec) according to manufacturer’s instructions. Flow thru
was collected and washed with staining buffer then stained for FACS. Samples
were sorted on a BD FACS Aria into serum supplemented media and stored on
ice. Sorted samples were centrifuged and resuspended in 100-200ul PBS for
retroorbital injection into recipient B6.SJL mice.

BrdU Administration and Staining: Mice were injected IP with 200 ul of 3
mg/ml BrdU in PBS at 12 hour intervals for 3 days. Mice subsequently were
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given drinking water with 1mg/ml sucrose and 0.5 mg/ml BrdU until takedown.
Splenocytes were harvested and stained as described prior then prepared for
intracellular staining with the Fix and Perm Cell Fixation and Permeabilization Kit
(ThermoFisher) according to manufacturer’s instructions. After ICS, cells were
treated with DNAse solution for 40 minutes, washed, and stained with anti-BrdU
APC antibody (BD) for 40 minutes at 1:80 dilution in FACS buffer. Cells were
washed and stored at 4 degrees in the dark until running on the cytometer.

QUANTIFICATION AND STATISTICAL ANALYSIS:
All p values were determined using one of the following as mentioned in figure
legends: unpaired non-parametric t-test or paired t-test using GraphPad Prism
version 7 or version 8 (GraphPad Software, La Jolla, CA 92037 USA). ns=not
significant, *p < 0.05, **p < 0.01, ****p < 0.001. Data are represented as mean ±
SEM or mean± SD. The number of mice used in each experiment, as well as the
number of times an experiment was repeated, is mentioned in the figure legends.
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REAGENT or RESOURCE
Antibodies (clone)

SOURCE
Company

IDENTIFIER
Catalog number

CD11c (N418)
IgM (R6-60.2)
CD38 (90)
CD73 (TY/11.8)
GL7 (GL7)
CD80 (16-10A1)
PD-L2/CD273 (TY25)
Streptavidin BV421
Streptavidin AF647
CD138 (281-2)
IgD (11–26c.2a)
B220 (RA3-6B2)

Biolegend
BD Biosciences
eBioscience
Biolegend
Biolegend
Biolegend; BD Biosciences
Biolegend
Biolegend
Invitrogen
Biolegend; BD Biosciences
Biolegend
Biolegend; eBioscience

CD19 (1D3)

eBioscience; BD
Biosciences
Biolegend
Sigma-Aldrich
Biolegend
Biolegend
Biolegend
Biolegend

117318 or 117333
562565
56-0381-82
127231, 127215 or 127230
144619
104731 or 104708; 563687
107206
405226
S32357
142516; 553713
405725 or 405731
103207, 103226 or 103246;
47-0452-82
35-0193-82; 557655 or
550992
115543
L7381-1MG
152612
110743
109814 or 109832
126515

CD19 (6D5)
peanut agglutinin–FITC
CD95 (SA367H8)
CD45.1 (A20)
CD45.2 (104)
CD183/CXCR3 (CXCR3173)
CD3 (17A2)
CD8a (53-6.7)
CD4 (H129.19)
CD4 (RM4-5)
F4/80 (BM8)
Ly-6G/GR1 (RB6-8C5)
Ter-119 (Ter-119)
Zombie Aqua fixable viability
kit
Mouse Fc fragment

Biolegend
BD Biosciences;
eBioscience
Biolegend
eBioscience
Invitrogen; eBioscience
Biolegend; BD Biosciences
Biolegend
Biolegend

100209
553034; 13-0081-85

Jackson Immunoresearch

015-000-008

Bacterial and Virus Strains
Influenza strain A/Puerto
Rico/8/1934 (PR8)

American Type Culture
Collection

Biological Samples
Turkey Erythrocytes

Lampire Biologicals

Chemicals, Peptides, and
Recombinant Proteins
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130312
13-0042-85
15-4801-82; 15-4801-82
108410; 553125
116204
423102

Cat# 7209401

Recombinant hemagglutinin
PR8 (HA-PR8)
HA-specific monoclonal
antibodies (IgG1 and
IgG2a/c)
H6/H1 chimeric constructs
Meloxicam

Laboratory of Dr. Barney
Graham, National Institute
of Allergy and Infectious
Disease
Laboratory of Dr. Jonathan
Yewdell, National Institute of
Allergy and Infectious
Diseases
Laboratory of Scott E.
Hensley, University of
Pennsylvania
Boehringer Ingelheim

Whittle et al., 2014

Margine et al., 2013

Reckitt Benckiser
Aurobindo

NDC 0010-601301
NDC 12496-0757-1
NDC 65862-496-47

Phoenix
Sigma-Aldrich
Sigma-Aldrich

0010250
T5648
C5135

Miltenyi Biotec
Miltenyi Biotec
ThermoFisher

130-048-101
130-042-901
GAS003

BD Biosciences

552598

The Jackson Laboratory

MGI:5656552
Jax Stock No: 002014
Jax Stock No: 022741

Mouse: Tbx21creERT2
ZsGreen
LSL/tdTomato
Rosa26

The Jackson Laboratory
from the laboratory of E.
John Wherry, University of
Pennsylvania
from the laboratory of E.
John Wherry, University of
Pennsylvania
from the laboratory of
Jinfang Zhu, National
Institutes of Health
from the laboratory of
Jinfang Zhu, National
Institutes of Health

Software and Algorithms
FlowJo

v9 and v10

Prism

V7 and V8

Becton Dickinson Co.,
Ashland, OR
GraphPad, La Jolla, CA

Buprenorphine HCl
Sulfamethoxazole and
Trimethoprim Oral
Suspension
Isoflurane
Tamoxifen
Kolliphor
Critical Commercial Assays
Streptavidin MicroBeads
LD Columns
Fix and Perm Cell Fixation
and Permeabilization Kit
APC BrdU Flow Kit
Experimental Models:
Organisms/Strains
Mouse: C57BL/6
Mouse: B6.SJL
flox/flox
Mouse: Tbx21
Mouse: Cd19

cre/+

Mouse: Tbx21-ZsGreen

Table 1: List of Key Resources
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MGI:1931143
Zhu et al., 2012;
MGI:5690118
Yu et al., 2015;
MGI:5690125; MGI:3809524
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